CA2388982A1 - Microtiter plate (mtp) based high throughput screening (hts) assays - Google Patents
Microtiter plate (mtp) based high throughput screening (hts) assays Download PDFInfo
- Publication number
- CA2388982A1 CA2388982A1 CA002388982A CA2388982A CA2388982A1 CA 2388982 A1 CA2388982 A1 CA 2388982A1 CA 002388982 A CA002388982 A CA 002388982A CA 2388982 A CA2388982 A CA 2388982A CA 2388982 A1 CA2388982 A1 CA 2388982A1
- Authority
- CA
- Canada
- Prior art keywords
- molecule
- cell
- dna
- interest
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003556 assay Methods 0.000 title claims abstract description 77
- 238000013537 high throughput screening Methods 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 150
- 230000012010 growth Effects 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims description 286
- 108090000623 proteins and genes Proteins 0.000 claims description 91
- 108020004414 DNA Proteins 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 80
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 79
- 229920001184 polypeptide Polymers 0.000 claims description 68
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 62
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 61
- 239000013598 vector Substances 0.000 claims description 59
- 229940088598 enzyme Drugs 0.000 claims description 52
- 102000004190 Enzymes Human genes 0.000 claims description 50
- 108090000790 Enzymes Proteins 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 44
- 230000002538 fungal effect Effects 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 239000004382 Amylase Substances 0.000 claims description 30
- 108010065511 Amylases Proteins 0.000 claims description 30
- 230000009261 transgenic effect Effects 0.000 claims description 28
- 102000013142 Amylases Human genes 0.000 claims description 26
- 235000019418 amylase Nutrition 0.000 claims description 26
- 239000000758 substrate Substances 0.000 claims description 22
- 239000003599 detergent Substances 0.000 claims description 20
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- 240000006439 Aspergillus oryzae Species 0.000 claims description 17
- 241000228245 Aspergillus niger Species 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 15
- 239000004753 textile Substances 0.000 claims description 15
- 108010059892 Cellulase Proteins 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 244000063299 Bacillus subtilis Species 0.000 claims description 12
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 241000351920 Aspergillus nidulans Species 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 11
- 235000010980 cellulose Nutrition 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- -1 haloperoxidase Proteins 0.000 claims description 9
- 241000194108 Bacillus licheniformis Species 0.000 claims description 8
- 239000011324 bead Substances 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 238000002875 fluorescence polarization Methods 0.000 claims description 8
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 7
- 108090001060 Lipase Proteins 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 102000004882 Lipase Human genes 0.000 claims description 6
- 239000004367 Lipase Substances 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 235000019421 lipase Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 102100022624 Glucoamylase Human genes 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 241001328122 Bacillus clausii Species 0.000 claims description 4
- 108010029541 Laccase Proteins 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000011343 solid material Substances 0.000 claims description 4
- 108010011619 6-Phytase Proteins 0.000 claims description 3
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 3
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 3
- 108010015776 Glucose oxidase Proteins 0.000 claims description 3
- 239000004366 Glucose oxidase Substances 0.000 claims description 3
- 108010028921 Lipopeptides Proteins 0.000 claims description 3
- 102000003992 Peroxidases Human genes 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 229940116332 glucose oxidase Drugs 0.000 claims description 3
- 235000019420 glucose oxidase Nutrition 0.000 claims description 3
- 230000003278 mimic effect Effects 0.000 claims description 3
- 229940072417 peroxidase Drugs 0.000 claims description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 3
- 229940085127 phytase Drugs 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 238000004448 titration Methods 0.000 claims description 3
- 108010031396 Catechol oxidase Proteins 0.000 claims description 2
- 102000030523 Catechol oxidase Human genes 0.000 claims description 2
- 102000004366 Glucosidases Human genes 0.000 claims description 2
- 108010056771 Glucosidases Proteins 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 108010054377 Mannosidases Proteins 0.000 claims description 2
- 102000001696 Mannosidases Human genes 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 108060008539 Transglutaminase Proteins 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 2
- 108010089934 carbohydrase Proteins 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 230000009036 growth inhibition Effects 0.000 claims description 2
- 229940059442 hemicellulase Drugs 0.000 claims description 2
- 108010002430 hemicellulase Proteins 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 239000001573 invertase Substances 0.000 claims description 2
- 235000011073 invertase Nutrition 0.000 claims description 2
- 238000006317 isomerization reaction Methods 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 230000002351 pectolytic effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 102000003601 transglutaminase Human genes 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 68
- 241000196324 Embryophyta Species 0.000 description 45
- 108010076504 Protein Sorting Signals Proteins 0.000 description 38
- 108091026890 Coding region Proteins 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 241000233866 Fungi Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 238000013518 transcription Methods 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 230000003248 secreting effect Effects 0.000 description 16
- 230000010076 replication Effects 0.000 description 14
- 241000228212 Aspergillus Species 0.000 description 13
- 230000001105 regulatory effect Effects 0.000 description 13
- 230000009466 transformation Effects 0.000 description 13
- 241000589158 Agrobacterium Species 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 108010020132 microbial serine proteinases Proteins 0.000 description 11
- 230000008488 polyadenylation Effects 0.000 description 11
- 210000001938 protoplast Anatomy 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 229920000742 Cotton Polymers 0.000 description 10
- 241000223218 Fusarium Species 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 8
- 108010084185 Cellulases Proteins 0.000 description 8
- 102000005575 Cellulases Human genes 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 229940072056 alginate Drugs 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 7
- 108010011756 Milk Proteins Proteins 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101710091688 Patatin Proteins 0.000 description 5
- 241000228143 Penicillium Species 0.000 description 5
- 244000061456 Solanum tuberosum Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229960002086 dextran Drugs 0.000 description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 description 4
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000221960 Neurospora Species 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 241000235403 Rhizomucor miehei Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 241000223259 Trichoderma Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 108010048241 acetamidase Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 3
- 108010037870 Anthranilate Synthase Proteins 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 101000757144 Aspergillus niger Glucoamylase Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000223221 Fusarium oxysporum Species 0.000 description 3
- 241000221779 Fusarium sambucinum Species 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 241001480714 Humicola insolens Species 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 241000235395 Mucor Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000226677 Myceliophthora Species 0.000 description 3
- 241000233654 Oomycetes Species 0.000 description 3
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 229940025131 amylases Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000013102 re-test Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 2
- 102100034042 Alcohol dehydrogenase 1C Human genes 0.000 description 2
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 2
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 241000193422 Bacillus lentus Species 0.000 description 2
- 108091005658 Basic proteases Proteins 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000233652 Chytridiomycota Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101000796894 Coturnix japonica Alcohol dehydrogenase 1 Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000567163 Fusarium cerealis Species 0.000 description 2
- 241000146406 Fusarium heterosporum Species 0.000 description 2
- 101150108358 GLAA gene Proteins 0.000 description 2
- 101100369308 Geobacillus stearothermophilus nprS gene Proteins 0.000 description 2
- 101100080316 Geobacillus stearothermophilus nprT gene Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000780463 Homo sapiens Alcohol dehydrogenase 1C Proteins 0.000 description 2
- 241000223198 Humicola Species 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108700001094 Plant Genes Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101000968489 Rhizomucor miehei Lipase Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 241000223258 Thermomyces lanuginosus Species 0.000 description 2
- 241001494489 Thielavia Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241001149964 Tolypocladium Species 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 241000758405 Zoopagomycotina Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010061330 glucan 1,4-alpha-maltohydrolase Proteins 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229910021654 trace metal Inorganic materials 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000009105 vegetative growth Effects 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid Chemical compound CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001578974 Achlya <moth> Species 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- 101800002326 Adipokinetic hormone Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 241001136561 Allomyces Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000534414 Anotopterus nikparini Species 0.000 description 1
- 101100163849 Arabidopsis thaliana ARS1 gene Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 101710082738 Aspartic protease 3 Proteins 0.000 description 1
- 241001513093 Aspergillus awamori Species 0.000 description 1
- 101000961203 Aspergillus awamori Glucoamylase Proteins 0.000 description 1
- 101000690713 Aspergillus niger Alpha-glucosidase Proteins 0.000 description 1
- 101900127796 Aspergillus oryzae Glucoamylase Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 101150071434 BAR1 gene Proteins 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 101000775727 Bacillus amyloliquefaciens Alpha-amylase Proteins 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 101000695691 Bacillus licheniformis Beta-lactamase Proteins 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 101900040182 Bacillus subtilis Levansucrase Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000235432 Blastocladiella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000235172 Bullera Species 0.000 description 1
- 241000589638 Burkholderia glumae Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 102100021868 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100037633 Centrin-3 Human genes 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241001279801 Coelomomyces Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 241000490729 Cryptococcaceae Species 0.000 description 1
- 241000221199 Cryptococcus <basidiomycete yeast> Species 0.000 description 1
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 101100342470 Dictyostelium discoideum pkbA gene Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000228138 Emericella Species 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 101100385973 Escherichia coli (strain K12) cycA gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001136487 Eurotium Species 0.000 description 1
- 241000221207 Filobasidium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000223194 Fusarium culmorum Species 0.000 description 1
- 241000223195 Fusarium graminearum Species 0.000 description 1
- 241001112697 Fusarium reticulatum Species 0.000 description 1
- 241001014439 Fusarium sarcochroum Species 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 101100001650 Geobacillus stearothermophilus amyM gene Proteins 0.000 description 1
- 101100460773 Geobacillus stearothermophilus nprA gene Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000005561 Glufosinate Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101100295959 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) arcB gene Proteins 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 1
- 101000880522 Homo sapiens Centrin-3 Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000235087 Lachancea kluyveri Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 108010063653 Leghemoglobin Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241000321520 Leptomitales Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 101150068888 MET3 gene Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100379123 Mus musculus Npr1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 101100022915 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-11 gene Proteins 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100378536 Ovis aries ADRB1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000194109 Paenibacillus lautus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710163504 Phaseolin Proteins 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000016227 Protein disulphide isomerases Human genes 0.000 description 1
- 108050004742 Protein disulphide isomerases Proteins 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 241000221535 Pucciniales Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 101900354623 Saccharomyces cerevisiae Galactokinase Proteins 0.000 description 1
- 101001035673 Saccharomyces cerevisiae Heme-responsive zinc finger transcription factor HAP1 Proteins 0.000 description 1
- 235000001006 Saccharomyces cerevisiae var diastaticus Nutrition 0.000 description 1
- 244000206963 Saccharomyces cerevisiae var. diastaticus Species 0.000 description 1
- 241000204893 Saccharomyces douglasii Species 0.000 description 1
- 241001407717 Saccharomyces norbensis Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235344 Saccharomycetaceae Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241001326564 Saccharomycotina Species 0.000 description 1
- 241000605112 Scapanulus oweni Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101100097319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ala1 gene Proteins 0.000 description 1
- 101100022918 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sua1 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000228389 Sporidiobolus Species 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 241001468239 Streptomyces murinus Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001540751 Talaromyces ruber Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101100157012 Thermoanaerobacterium saccharolyticum (strain DSM 8691 / JW/SL-YS485) xynB gene Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 241001495429 Thielavia terrestris Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000223260 Trichoderma harzianum Species 0.000 description 1
- 241000378866 Trichoderma koningii Species 0.000 description 1
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 241000221561 Ustilaginales Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 101900163555 Yarrowia lipolytica Dibasic-processing endoprotease Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 101150009206 aprE gene Proteins 0.000 description 1
- 101150008194 argB gene Proteins 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940106135 cellulose Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 108091006044 chimera Proteins 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 235000019571 color Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 101150005799 dagA gene Proteins 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010042194 dextransucrase Proteins 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003455 independent Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 101150039489 lysZ gene Proteins 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 101150105920 npr gene Proteins 0.000 description 1
- 101150017837 nprM gene Proteins 0.000 description 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108090000021 oryzin Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 101150110790 xylB gene Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01091—Cellulose 1,4-beta-cellobiosidase (3.2.1.91)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention is to provide a method to perform assays that efficiently and accurately can screen large numbers of cell populations producing variants of a molecule of interest. In a first aspect the invention relates to a method for high throughput screening (HTS) of a large population of host cells for production of a molecule of interest, the method comprising the steps of: a) arranging the host cells in a spatial array so each position in the spatial array is occupied by one cell, b) cultivating the host cells under growth conditions suitable for HTS, c) assaying each array position for production of the molecule of interest, and d) selecting the cells from those positions where the molecule was produced, as determined in step c).
Description
Microtiter plate (MTP) based High Throughput Screening (HTS) assays Field of invention s Technologies such as DNA shuffling, random DNA mutagenesis and in vivo recombination have allowed the generation of enor-mous populations of variant cells that produce variants of a certain protein, RNA, or small molecule. In addition, it has become possible in recombinant host strains to establish large io libraries of natural enzymes cloned from other organisms. To-gether these technologies have created a need for assays that efficiently and accurately can screen large numbers of vari-ants, high troughput screening (HTS) assays.
i5 Background of the invention Historically, biological assays have been developed and op-timized with regard to sensitivity, linearity and simplicity.
However, if these assays are to be transformed into high throughput screens for substances produced by large populations 2o cell cultures, a number of difficulties must be overcome. Exam-ples of difficulties encountered when using e.g. a microtiter plate based screening assay include: a) differential growth and/or gene expression of identical clones in the separate wells of the microtiter plate, b) differential growth and/or 25 gene expression of different clones, c) differential stress ex-posure (eg. heat treatment, humidity) across the plate, d) ef-fects of cell-material or growth medium on the assay. In the past, efficient and accurate high throughput screening has been hampered by the inability to work around such difficulties.
so Below we describe a method of performing an assay that has been specifically developed for the screening of large popula-tions of clones producing variants of a given protein.
Summary of the invention The problem to be solved by the present invention is to pro-vide a method to perform assays that efficiently and accurately can screen large numbers of cell populations producing variants of a molecule of interest.
In a first aspect the invention relates to a method for high throughput screening (HTS) of a large population of host cells for production of a molecule of interest, the method com-prising the steps of:
a) arranging the host cells in a spatial array so each posi-io tion in the spatial array is occupied by one cell, b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and i5 d) selecting the cells from those positions where the mole-cule was produced, as determined in step c).
In a second aspect the invention relates to a method for screening a DNA library for DNA of interest, the method com 2o prising the steps of:
a) creating host cells comprising the DNA library, b) using the method described in the first aspect to assay for a host cell producing a molecule of interest; wherein the host cell comprises the DNA of interest.
Further, in a third aspect the invention relates to a recom-binant vector comprising DNA isolated by a method as defined in the preceding aspect.
In a fourth aspect the invention also relates to a recombi 3o nant host cell comprising DNA isolated by a method as described in the second aspect or the vector according to the third as pect.
Also a fifth aspect relates to a transgenic animal contain ing and expressing the DNA of interest according to any of the second, third or fourth aspect.
i5 Background of the invention Historically, biological assays have been developed and op-timized with regard to sensitivity, linearity and simplicity.
However, if these assays are to be transformed into high throughput screens for substances produced by large populations 2o cell cultures, a number of difficulties must be overcome. Exam-ples of difficulties encountered when using e.g. a microtiter plate based screening assay include: a) differential growth and/or gene expression of identical clones in the separate wells of the microtiter plate, b) differential growth and/or 25 gene expression of different clones, c) differential stress ex-posure (eg. heat treatment, humidity) across the plate, d) ef-fects of cell-material or growth medium on the assay. In the past, efficient and accurate high throughput screening has been hampered by the inability to work around such difficulties.
so Below we describe a method of performing an assay that has been specifically developed for the screening of large popula-tions of clones producing variants of a given protein.
Summary of the invention The problem to be solved by the present invention is to pro-vide a method to perform assays that efficiently and accurately can screen large numbers of cell populations producing variants of a molecule of interest.
In a first aspect the invention relates to a method for high throughput screening (HTS) of a large population of host cells for production of a molecule of interest, the method com-prising the steps of:
a) arranging the host cells in a spatial array so each posi-io tion in the spatial array is occupied by one cell, b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and i5 d) selecting the cells from those positions where the mole-cule was produced, as determined in step c).
In a second aspect the invention relates to a method for screening a DNA library for DNA of interest, the method com 2o prising the steps of:
a) creating host cells comprising the DNA library, b) using the method described in the first aspect to assay for a host cell producing a molecule of interest; wherein the host cell comprises the DNA of interest.
Further, in a third aspect the invention relates to a recom-binant vector comprising DNA isolated by a method as defined in the preceding aspect.
In a fourth aspect the invention also relates to a recombi 3o nant host cell comprising DNA isolated by a method as described in the second aspect or the vector according to the third as pect.
Also a fifth aspect relates to a transgenic animal contain ing and expressing the DNA of interest according to any of the second, third or fourth aspect.
A sixth aspect relates to a transgenic plant containing and expressing the DNA of interest according to any of the second, third or fourth aspect.
A seventh aspect relates to a method of producing a molecule s of interest, which method comprises cultivating a cell accord-ing to any of the first or fourth aspects in suitable culture medium under conditions permitting expression of the DNA of in-terest and recovering the resulting molecule from the culture medium.
io An eigth aspect relates to a method of producing a molecule of interest, which method comprises recovering the molecule from any part or secrete of/from the transgenic animal accord-ing to the fifth aspect.
A final aspect relates to a method of producing a molecule is of interest, which method comprises growing a cell of a trans-genic plant according to the sixth aspect, and recovering the molecule from the resulting plant.
Definitions 2o Prior to a discussion of the detailed embodiments of the in-vention is provided a definition of specific terms related to the main aspects of the invention.
In accordance with the present invention there may be em ployed conventional molecular biology, microbiology, and recom 25 binant DNA techniques within the skill of the art. Such tech niques are explained fully in the literature. See, e.g., Sam-brook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Man-ual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989") 3o DNA Cloning: A Practical Approach, Volumes I and II /D. N.
Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed.
1984); Nucleic Acid Hybridization (B. D. Hames & S.J. Higgins eds (1985)); Transcription And Translation (B. D. Hames & S.J.
Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed.
A seventh aspect relates to a method of producing a molecule s of interest, which method comprises cultivating a cell accord-ing to any of the first or fourth aspects in suitable culture medium under conditions permitting expression of the DNA of in-terest and recovering the resulting molecule from the culture medium.
io An eigth aspect relates to a method of producing a molecule of interest, which method comprises recovering the molecule from any part or secrete of/from the transgenic animal accord-ing to the fifth aspect.
A final aspect relates to a method of producing a molecule is of interest, which method comprises growing a cell of a trans-genic plant according to the sixth aspect, and recovering the molecule from the resulting plant.
Definitions 2o Prior to a discussion of the detailed embodiments of the in-vention is provided a definition of specific terms related to the main aspects of the invention.
In accordance with the present invention there may be em ployed conventional molecular biology, microbiology, and recom 25 binant DNA techniques within the skill of the art. Such tech niques are explained fully in the literature. See, e.g., Sam-brook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Man-ual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989") 3o DNA Cloning: A Practical Approach, Volumes I and II /D. N.
Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed.
1984); Nucleic Acid Hybridization (B. D. Hames & S.J. Higgins eds (1985)); Transcription And Translation (B. D. Hames & S.J.
Higgins, eds. (1984)); Animal Cell Culture (R.I. Freshney, ed.
(1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B.
Perbal, A Practical Guide To Molecular Cloning (1984).
Isolated: When applied to a protein, the term "isolated" indi-Gates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue.
In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal ori-gin. It is preferred to provide the proteins in a highly puri-io fied form, i.e., greater than 95o pure, more preferably greater than 99% pure. When applied to a polynucleotide molecule, the term "isolated" indicates that the molecule is removed from its natural genetic milieu, and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use i5 within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Iso-lated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, and may in-2o clude naturally occurring 5' and 3' un-translated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316: 774-78, 1985).
25 A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or pre-pared from a combination of natural and synthetic molecules.
A "nucleic acid molecule" refers to the phosphate ester poly-meric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (de-oxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine;
"DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA
helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term s includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e. g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular dou-ble-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence io in the 5' to 3' direction along the non-transcribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.
i5 A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a zo translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic se-quences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA se-quences. If the coding sequence is intended for expression in a 25 eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
Expression vector: A DNA molecule, linear or circular, that 3o comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcrip-tion. Such additional segments may include promoter and termi-nator sequences, and optionally one or more origins of replica-tion, one or more selectable markers, an enhancer, a polyade-3s nylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
Transcriptional and translational control sequences are DNA
s regulatory sequences, such as promoters, enhancers, termina-tors, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.
io A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory i5 peptide during transit through the secretory pathway.
The term "promoter" is used herein for its art-recognized mean-ing to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of zo transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.
"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert 2s for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
A coding sequence is "under the control" of transcriptional and 3o translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the cod-ing sequence.
35 "Isolated polypeptide": is a polypeptide which is essentially free of other non-[enzyme] polypeptides, e.g., at least about 20% pure, preferably at least about 40e pure, more preferably about 60% pure, even more preferably about 80% pure, most pref-erably about 90% pure, and even most preferably about 95°s pure, as determined by SDS-PAGE.
"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the he-terologous DNA includes a gene foreign to the cell.
io A cell has been "transfected" by exogenous or heterologous DNA
when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. Preferably, the transforming DNA should be integrated (covalently linked) into i5 chromosomal DNA making up the genome of the cell.
A "clone" is a population of cells derived from a single cell or common ancestor by mitosis.
20 "Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vec-tor targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to 2s sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.
3o Nucleic Acid Sequence The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and in-clude isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences 35 of the present invention from such genomic DNA can be effected, e.g., by using the well-known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., In-nis et al., 1990, A Guide to Methods and Application, Academic Press, New York. Other nucleic acid amplification procedures s such as ligase chain reaction (LCR), ligated activated tran-scription (LAT) and nuceic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be cloned from a strain. producing the polypeptide, or from another re-lated organism and thus, for example, may be an allelic or spe-io cies variant of the polypeptide encoding region of the nucleic acid sequence.
The term "isolated" nucleic acid sequence as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20o pure, i5 preferably at least about 40% pure, more preferably about 60%
pure, even more preferably about 80o pure, most preferably about 90% pure, and even most preferably about 95o pure, as de-termined by agarose gel electorphoresis. For example, an iso-lated nucleic acid sequence can be obtained by standard cloning zo procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment com-prising the nucleic acid sequence encoding the polypeptide, in-25 sertion of the fragment into a vector molecule, and incorpora-tion of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be repli-cated. The nucleic acid sequence may be of genomic, cDNA, RNA, semi-synthetic, synthetic origin, or any combinations thereof.
Nucleic Acid Construct As used herein the term "nucleic acid construct" is in tended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is in tended to indicate a nucleic acid segment which may be single or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence encoding a po lypeptide of interest. The construct may optionally contain s other nucleic acid segments.
The DNA of interest may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide io probes in accordance with standard techniques (cf. Sambrook et al., supra).
The nucleic acid construct may also be prepared syntheti-cally by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters i5 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phos-phoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and clo-ned in suitable vectors.
2o Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed ge nomic and cDNA origin prepared by ligating fragments of syn thetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid con 25 struct, in accordance with standard techniques.
The nucleic acid construct may also be prepared by poly-merase chain reaction using specific primers, for instance as described in US 4, 683, 202 or Saiki et al . , Science 239 (1988) , 487 - 491.
3o The term nucleic acid construct may be synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding se-quence" as defined herein is a sequence which is transcribed 35 into mRNA and translated into a polypeptide of the present invention when placed under the control of the above mentioned control sequences. The boundaries of the coding sequence are generally determined by a translation start codon ATG at the 5'-terminus and a translation stop codon at the 3'-terminus. A
coding sequence can include, but is not limited to, DNA, cDNA, s and recombinant nucleic acid sequences.
The term "control sequences" is defined herein to include all components which are necessary or advantageous for expres-sion of the coding sequence of the nucleic acid sequence . Each control sequence may be native or foreign to the nucleic acid io sequence encoding the polypeptide. Such control sequences in-clude, but are not limited to, a leader, a polyadenylation se-quence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control se-quences include a promoter, and transcriptional and transla-i5 tional stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction si-tes facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypep-tide.
2o The control sequence may be an appropriate promoter se-quence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control se-quences which mediate the expression of the polypeptide. The 25 promoter may be any nucleic acid sequence which shows tran-scriptional activity in the host cell of choice and may be ob-tained from genes encoding extracellular or intracellular poly-peptides either homologous or heterologous to the host cell.
The control sequence may also be a suitable transcription so terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
35 The control sequence may also be a polyadenylation se-quence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in s the present invention.
The control sequence may also be a signal peptide-coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the ex-pressed polypeptide into the cell's secretory pathway of the io host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide-coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted poly-peptide. Alternatively, the 5' end of the coding sequence may i5 contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted poly-peptide. A foreign signal peptide-coding region may be required where the coding sequence does not normally contain a signal peptide-coding region. Alternatively, the foreign signal pep-ao tide coding region may simply replace the natural signal pep-tide coding region in order to obtain enhanced secretion rela-tive to the natural signal peptide coding region normally asso-ciated with the coding sequence. The signal peptide-coding re-gion may be obtained from a glucoamylase or an amylase gene is from an Aspergillus species, a lipase or proteinase gene from a Rhizomucor species, the gene for the alpha-factor from Sac-charomyces cerevisiae, an amylase or a protease gene from a Ba-cillus species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed 3o polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.
The control sequence may also be a propeptide coding re-gion, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is 35 known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be con-verted to mature active polypeptide by catalytic or autocata-lytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the Bacillus sub-tilis alkaline protease gene (aprE), the Bacillus subtilis neu-tral protease gene (nprT), the Saccharomyces cerevisiae alpha-factor gene, or the Myceliophthora thermophilum laccase gene (WO 95/33836).
The nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode io one or more factors that are advantageous in the expression of the polypeptide, e.g., an activator (e. g., a trans-acting fac-tor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention. The nucleic acids encoding one or more of is these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.
An activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla et al., 1990, EMBO Journal 9:1355-1364; Jarai and Buxton, 1994, 2o Current Genetics 26:2238-244; Verdier, 1990, Yeast 6:271-297).
The nucleic acid sequence encoding an activator may be obtained from the genes encoding Bacillus stearothermophilus NprA
(nprA), Saccharomyces cerevisiae heme activator protein 1 (haply, Saccharomyces cerevisiae galactose metabolizing protein 25 4 (gal4), and Aspergillus nidulans ammonia regulation protein (areA). For further examples, see Verdier, 1990, supra and MacKenzie et al., 1993, Journal of General Microbiology 139:2295-2307.
A chaperone is a protein which assists another polypep 3o tide in folding properly (Hartl et al., 1994, TIBS 19:20-25;
Bergeron et al., 1994, TIBS 19:124-128; Demolder et al., 1994, Journal of Biotechnology 32:179-189; Craig, 1993, Science 260:1902-1903; Gething and Sambrook, 1992, Nature 355:33-45;
Puig and Gilbert, 1994, Journal of Biological Chemistry 35 269:7764-7771; Wang and Tsou, 1993, The FASEB Journal 7:1515-11157; Robinson et al., 1994, Bio/Technology 1:381-384). The nucleic acid sequence encoding a chaperone may be obtained from the genes encoding Bacillus subtilis GroE proteins, Aspergillus oryzae protein disulphide isomerase, Saccharomyces cerevisiae s calnexin, Saccharomyces cerevisiae BiP/GRP78, and Saccharomyces cerevisiae Hsp70. For further examples, see Gething and Sam-brook, 1992, supra, and Hartl et al., 1994, supra.
A processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypep io tide (Enderlin and Ogrydziak, 1994, Yeast 10:67-79; Fuller et al., 1989, Proceedings of the National Academy of Sciences USA
86:1434-1438; Julius et al., 1984, Cell 37:1075-1089; Julius et al., 1983, Cell 32:839-852). The nucleic acid sequence encoding a processing protease may be obtained from the genes encoding i5 Aspergillus niger Kex2, Saccharomyces cerevisiae dipepti-dylaminopeptidase, Saccharomyces cerevisiae Kex2, and Yarrowia lipolytica dibasic processing endoprotease (xpr6).
It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide 2o relative to the growth of the host cell. Examples of regula tory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
Regulatory systems in prokaryotic systems would include the z5 lac, tac, and trp operator systems . In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA al-pha-amylase promoter, Aspergillus niger glucoamylase promoter, and the Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences 3o are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metal lothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide 35 would be placed in tandem with the regulatory sequence.
Promoters Examples of suitable promoters for directing the tran-scription of the nucleic acid constructs of the present inven tion, especially in a bacterial host cell, are the promoters obtained from the E. coli lac operon, the Streptomyces coeli color agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus subtilis alkaline protease gene, the Bacillus licheniformis alpha-amylase gene (amyl), the Bacillus io stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), the Bacillus amy-loliquefaciens BAN amylase gene, the Bacillus licheniformis pe-nicillinase gene (penP), the Bacillus subtilis xylA and xylB
genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff i5 et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA
80:21-25) , or the Bacillus pumilus xylosidase gene, or by the phage Lambda PR or PL promoters or the E. coli lac, ~ or tac 2o promoters. Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.
Examples of suitable promoters for directing the tran scription of the nucleic acid constructs of the present inven 25 tion in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhi-zomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, As-pergillus niger or Aspergillus awamori glucoamylase (glaA), 3o Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusarium oxysporum trypsin-like protease (as described in U.S. Patent No. 4,288,627, which is incorpo-rated herein by reference), and hybrids thereof. Particularly 35 preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral a-amylase and As-pergillus oryzae triose phosphate isomerase), and glaA promot-ers. Further suitable promoters for use in filamentous fungus s host cells are the ADH3 promoter (McKnight et al . , The EMBO J.
4 (1985), 2093 - 2099) or the t~iA promoter.
Examples of suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080; Alber and Ka-io wasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434) or alcohol de-hydrogenase genes (Young et al., in Genetic Engineering of Mi-croorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., Nature 304 (1983), 652 - 654) promoters.
i5 Further useful promoters are obtained from the Saccharo-myces cerevisiae enolase (ENO-1) gene, the Saccharomyces cere-visiae galactokinase gene (GAL1), the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the Saccharomyces cerevisiae 3-zo phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8:423-488. In a mammalian host cell, useful promoters include viral promoters such as those from Simian Virus 40 (5V40) , Rous sar-coma virus (RSV), adenovirus, and bovine papilloma virus (BPV).
Examples of suitable promoters for directing the tran scription of the DNA encoding the polypeptide of the invention in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.
An example of a suitable promoter for use in insect cells is the polyhedrin promoter (US 4,745,051; Vasuvedan et al., FEBS Lett. 311, (1992) 7 - 11) , the P10 promoter (J.M. Vlak et al., J. Gen. Virology 69, 1988, pp. 765-776), the Autographa californica polyhedrosis virus basic protein promoter (EP 397 485), the baculovirus immediate early gene 1 promoter (US
5,155,037; US 5,162,222), or the baculovirus 39K delayed-early gene promoter (US 5,155,037; US 5,162,222).
s Terminators Preferred terminators for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA
amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and io Fusarium oxysporum trypsin-like protease for fungal hosts) the TPIl (Alber and Kawasaki, ~ cit.) or ADH3 (McKnight et al., op. cit.) terminators.
Preferred terminators for yeast host cells are obtained from the genes encoding Saccharomyces cerevisiae enolase, Sac is charomyces cerevisiae cytochrome C (CYC1), or Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other use-ful terminators for yeast host cells are described by Romanos et al., 1992, supra.
2o Polyadenylation Signals Preferred polyadenylation sequences for filamentous fun gal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergil lus nidulans anthranilate synthase, and Aspergillus niger al 25 pha-glucosidase.
Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Molecular Cellular Biology 15:5983-5990.
Polyadenylation sequences are well known in the art for 3o mammalian host cells such as SV40 or the adenovirus 5 Elb re gion.
Signal Sequences An effective signal peptide-coding region for bacterial 35 host cells is the signal peptide-coding region obtained from the maltogenic amylase gene from Bacillus NCIB 11837, the Ba cillus stearothermophilus alpha-amylase gene, the Bacillus licheniformis subtilisin gene, the Bacillus licheniformis beta-lactamase gene, the Bacillus stearothermophilus neutral prote-ases genes (nprT, nprS, nprM), and the Bacillus subtilis PrsA
s gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from Aspergillus oryzae TAKA amylase gene, Aspergillus niger io neutral amylase gene, the Rhizomucor miehei aspartic proteinase gene, the Humicola lanuginosa cellulase or lipase gene, or the Rhizomucor miehei lipase or protease gene, Aspergillus sp. amy-lase or glucoamylase, a gene encoding a Rhizomucor miehei li-pase or protease. The signal peptide is preferably derived from i5 a gene encoding A. oryzae TAKA amylase, A. niger neutral a-amylase, A. niger acid-stable amylase, or A. niger glucoamy-lase.
Useful signal peptides for yeast host cells are obtained 2o from the genes for Saccharomyces cerevisiae a-factor and Sac-charomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
For secretion from yeast cells, the secretory signal se quence may encode any signal peptide which ensures efficient 25 direction of the expressed polypeptide into the secretory path way of the cell. The signal peptide may be naturally occurring signal peptide, or a functional part thereof, or it may be a synthetic peptide. Suitable signal peptides have been found to be the a-factor signal peptide, the signal peptide of mouse 3o salivary amylase (cf . O. Hagenbuchle et al . , Nature 289, 1981, pp. 643-646), a modified carboxypeptidase signal peptide (cf.
L.A. Valls et al . , Cell 48, 1987, pp. 887-897) , the yeast BAR1 signal peptide (cf. WO 87/02670), or the yeast aspartic prote ase 3 (YAP3) signal peptide (cf. M. Egel-Mitani et al., Yeast 35 6, 1990, pp. 127-137).
For efficient secretion in yeast, a sequence encoding a leader peptide may also be inserted downstream of the signal sequence and upstream of the DNA sequence encoding the polypep-tide. The function of the leader peptide is to allow the ex-pressed polypeptide to be directed from the endoplasmic reticu-lum to the Golgi apparatus and further to a secretory vesicle for secretion into the culture medium (i.e. exportation of the polypeptide across the cell wall or at least through the cellu-lar membrane into the periplasmic space of the yeast cell). The io leader peptide may be the yeast a-factor leader (the use of which is described in e.g. US 4,546,082, EP 123 294, EP 123 544 and EP 163 529). Alternatively, the leader peptide may be a synthetic leader peptide, which is to say a leader peptide not found in nature. Synthetic leader peptides may, for instance, i5 be constructed as described in WO 89/02463 or WO 92/11378.
For use in insect cells, the signal peptide may conven-iently be derived from an insect gene (cf. WO 90/05783), such as the lepidopteran Manduca sexta adipokinetic hormone precur-sor signal peptide (cf. US 5,023,328).
Expression Vectors The present invention also relates to recombinant expres sion vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient re-striction sites to allow for insertion or substitution of the 3o nucleic acid sequence encoding the polypeptide at such sites.
Alternatively, the nucleic acid sequence of the present inven-tion may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appro-priate vector for expression. In creating the expression vec-tor, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.
The recombinant expression vector may be any vector (e. g., a plasmid or virus) which can be conveniently subjected s to recombinant DNA procedures and can bring about the expres sion of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector io may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a mini-chromosome, or an artificial chromosome. The vector may contain any means for assuring self-i5 replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosomes) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together zo contain the total DNA to be introduced into the genome of the host cell, or a transposon.
The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of z5 which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers which confer an-tibiotic resistance such as ampicillin, kanamycin, chloram-3o phenicol, tetracycline, neomycin, hygromycin or methotrexate resistance. A frequently used mammalian marker is the dihydro-folate reductase gene (DHFR). Suitable markers for yeast host cells are ADE2 , HIS3 , LEU2 , LYS2 , MET3 , TRPl , and URA3 . A se-lectable marker for use in a filamentous fungal host cell may 35 be selected from the group including, but not limited to, amdS
(acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phos-photransferase), niaD (nitrate reductase), pyre (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC
(anthranilate synthase), and glufosinate resistance markers, as s well as equivalents from other species. Preferred for use in an Aspergillus cell are the amdS and pyre markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomy ces hygroscopicus. Furthermore, selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where io the selectable marker is on a separate vector.
The vectors of the present invention preferably contain an elements) that permits stable integration of the vector into the host cell genome or autonomous replication of the vec-tor in the cell independent of the genome of the cell.
is The vectors of the present invention may be integrated into the host cell genome when introduced into a host cell.
For integration, the vector may rely on the nucleic acid se-quence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by 2o homologous or non-homologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for di-recting integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a pre-2s cise locations) in the chromosome(s). To increase the likeli-hood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nu-cleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1, 500 base pairs, and most preferably 800 to 1, 500 base pairs, 3o which are highly homologous with the corresponding target se-quence to enhance the probability of homologous recombination.
The integrational elements may be any sequence that is homolo-gous with the target sequence in the genome of the host cell.
Furthermore, the integrational elements may be non-encoding or 3s encoding nucleic acid sequences . On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
s For autonomous replication, the vector may further com-prise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacte-rial origins of replication are the origins of replication of plasmids pBR322, pUCl9, pACYC177, pACYC184, pUB110, pE194, io pTA1060, and pAMi3l. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a muta-tion which makes its functioning temperature-sensitive in the is host cell (see, e.g., Ehrlich, 1978, Proceedings of the Na-tional Academy of Sciences USA 75:1433).
More than one copy of a nucleic acid sequence encoding a polypeptide of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence.
zo Stable amplification of the nucleic acid sequence can be ob-tained by integrating at least one additional copy of the se-quence into the host cell genome using methods well known in the art and selecting for transformants.
The procedures used to ligate the elements described zs above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).
Host Cells 3o The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due 3s to mutations that occur during replication.
The cell is preferably transformed with a vector compris-ing a nucleic acid sequence of the invention followed by inte-gration of the vector into the host chromosome. "Transforma-tion" means introducing a vector comprising a nucleic acid se-quence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of io the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.
The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, e.g., a prokaryote, or i5 a non-unicellular microorganism, e.g., a eukaryote. Useful uni-cellular cells are bacterial cells such as gram positive bacte-ria including, but not limited to, a Bacillus cell, e.g., Ba-cillus alkalophilus, Bacillus amyloliquefaciens, Bacillus bre-vis, Bacillus circulans, Bacillus coagulans, Bacillus lautus, 2o Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces livi-dans or Streptomyces murinus, or gram negative bacteria such as E. coli and Pseudomonas sp. In a preferred embodiment, the bac-z5 terial host cell is a Bacillus lentus, Bacillus licheniformis, Bacillus stearothermophilus or Bacillus subtilis cell. The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using 3o competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electropora tion (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 35 1987, Journal of Bacteriology 169:5771-5278).
The host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or a fungal cell.
Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS
s cells, or any number of other immortalized cell lines avail able, e.g., from the American Type Culture Collection.
Examples of suitable mammalian cell lines are the COS (ATCC CRL
1650 and 1651), BHK (ATCC CRL 1632, 10314 and 1573, ATCC CCL
10), CHL (ATCC CCL39) or CHO (ATCC CCL 61) cell lines. Methods io of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159 (1982), 601 - 621; Southern and Berg, J . Mol . Appl . Genet . 1 ( 1982 ) , 32 7 - 341; Loyter et al . , Proc .
Natl. Acad. Sci. USA 79 (1982), 422 - 426; Wigler et al., Cell is 14 (1978), 725; Corsaro and Pearson, Somatic Cell Genetics 7 (1981), 603, Ausubel et al., Current Protocols in Molecular Bi ology, John Wiley and Sons, Inc., N.Y., 1987, Hawley-Nelson et al., Focus 15 (1993), 73; Ciccarone et al., Focus 15 (1993), 80; Graham and van der Eb, Virology 52 (1973), 456; and Neumann 2o et al., EMBO J. 1 (1982), 841 - 845.
In a preferred embodiment, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The zs Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawk-sworth et al., 1995, supra). Representative groups of Ascomy-cota include, e.g., Neurospora, Eupenicillium (=Penicillium), 3o Emericella (=Aspergillus), Eurotium (=Aspergillus), and the true yeasts listed above. Examples of Basidiomycota include mushrooms, rusts, and smuts. Representative groups of Chy-tridiomycota include, e.g., Allomyces, Blastocladiella, Coelo-momyces, and aquatic fungi. Representative groups of Oomycota 3s include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Examples of mitosporic fungi include Aspergil-lus, Penicillium, Candida, and Alternaria. Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
In a preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporogenous s yeast (Endomycetales), basidiosporogenous yeast, and yeast be longing to the Fungi Imperfecti (Blastomycetes). The ascosporo-genous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four sub-families, Schizosaccharomycoideae (e. g., genus Schizosaccharo-io myces), Nadsonioideae, Lipomycoideae, and Saccharomycoideae (e.g., genera Pichia, Kluyveromyces and Saccharomyces). The basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidi-ella. Yeasts belonging to the Fungi Imperfecti are divided i5 into two families, Sporobolomycetaceae (e. g., genera Sorobolo-myces and Bullera) and Cryptococcaceae (e. g., genus Candida).
Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as de-scribed in Biology and Activities of Yeast (Skinner, F.A., zo Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol.
Symposium Series No. 9, 1980. The biology of yeast and manipu-lation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B.J., and Stopani, A.O.M., editors, 2nd edition, 1987; The Yeasts, 25 Rose, A.H., and Harrison, J.S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast Saccharomyces, Strathern et al., editors, 1981).
The yeast host cell may be selected from a cell of a spe cies of Candida, Kluyveromyces, Saccharomyces, Schizosaccharo 3o myces, Candida, Pichia, Hansehula, or Yarrowia. In a preferred embodiment, the yeast host cell is a Saccharomyces carlsbergen-sis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Sac-charomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis or Saccharomyces oviformis cell. Other useful yeast 35 host cells are a Kluyveromyces lactis Kluyveromyces fragilis Hansehula polymorpha, Pichia pastoris Yarrowia lipolytica, Schizosaccharomyces pombe, Ustilgo maylis, Candida maltose, Pichia guillermondii and Pichia methanolio cell (cf. Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465; US 4,882,279 s and US 4,879,231).
In a preferred embodiment, the fungal host cell is a fil-amentous fungal cell. "Filamentous fungi" include all filamen-tous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are io characterized by a vegetative mycelium composed of chitin, cel-lulose, glucan, chitosan, mannan, and other complex polysaccha-rides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding is of a unicellular thallus and carbon catabolism may be fermenta-tive. In a more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, Acre-monium, Aspergillus, Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium, Thielavia, Tolypocladium, and Tricho-2o derma or a teleomorph or synonym thereof . In an even more pre-ferred embodiment, the filamentous fungal host cell is an As-pergillus cell. In another even more preferred embodiment, the filamentous fungal host cell is an Acremonium cell. In another even more preferred embodiment, the filamentous fungal host z5 cell is a Fusarium cell. In another even more preferred embodi-ment, the filamentous fungal host cell is a Humicola cell. In another even more preferred embodiment, the filamentous fungal host cell is a Mucor cell. In another even more preferred em-bodiment, the filamentous fungal host cell is a Myceliophthora 3o cell. In another even more preferred embodiment, the filamen-tous fungal host cell is a Neurospora cell. In another even more preferred embodiment, the filamentous fungal host cell is a Penicillium cell. In another even more preferred embodiment, the filamentous fungal host cell is a Thielavia cell. In an-other even more preferred embodiment, the filamentous fungal host cell is a Tolypocladium cell. In another even more pre-ferred embodiment, the filamentous fungal host cell is a Trichoderma cell. In a most preferred embodiment, the filamen-tous fungal host cell is an Aspergillus awamori, Aspergillus s foetidus, Aspergillus japonicas, Aspergillus niger, Aspergillus nidulans or Aspergillus oryzae cell. In another most preferred embodiment, the filamentous fungal host cell is a Fusarium cell of the section Discolor (also known as the section Fusarium).
For example, the filamentous fungal parent cell may be a Fusa-io rium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sulphureum, or Fusarium trichothecioides cell. In an-ts other preferred embodiment, the filamentous fungal parent cell is a Fusarium strain of the section Elegans, e.g., Fusarium ox-ysporum. In another most preferred embodiment, the filamentous fungal host cell is a Humicola insolens or Humicola lanuginosa cell. In another most preferred embodiment, the filamentous 2o fungal host cell is a Mucor miehei cell. In another most pre-ferred embodiment, the filamentous fungal host cell is a My-celiophthora thermophilum cell. In another most preferred em-bodiment, the filamentous fungal host cell is a Neurospora crassa cell. In another most preferred embodiment, the filamen-ts tous fungal host cell is a Penicillium purpurogenum cell. In another most preferred embodiment, the filamentous fungal host cell is a Thielavia terrestris cell or an Acremonium chry-sogenum cell. In another most preferred embodiment, the Tricho-derma cell is a Trichoderma harzianum, Trichoderma koningii, 3o Trichoderma longibrachiatum, Trichoderma reesei or Trichoderma viride cell. The use of Aspergillus spp. for the expression of proteins is described in, e.g., EP 272 277, EP 230 023.
3s Transformation Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suit-able procedures for transformation of Aspergillus host cells s are described in EP 238 023 and Yelton et al., 1984, Proceed-ings of the National Academy of Sciences USA 81:1470-1474. A
suitable method of transforming Fusarium species is described by Malardier et al., 1989, Gene 78:147-156 or in co-pending US
Serial No. 08/269,449. Examples of other fungal cells are cells io of filamentous fungi, e.g. Aspergillus spp., Neurospora spp., Fusarium spp. or Trichoderma spp., in particular strains of A.
oryzae, A. nidulans or A. niger. The use of Aspergillus spp.
for the expression of proteins is described in, e.g., EP 272277 or EP 230023. The transformation of F. oxysporum may for in-i5 stance be carried out as described by Malardier et al., 1989, Gene 78: 147-156. The transformation of Trichoderma spp. may be performed as known in the art.
Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., edi 2o tors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153:163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75:1920. Mammalian cells may be transformed by di-25 rect uptake using the calcium phosphate precipitation method of Graham and Van der Eb (1978, Virology 52:546).
Transformation of insect cells and production of het-erologous polypeptides therein may be performed as described in US 4,745,051; US 4,775,624; US 4,879,236; US 5,155,037; US
30 5,162,222; EP 397,485, all of which are incorporated herein by reference. The insect cell line used as the host may suitably be a Lepidoptera cell line, such as Spodoptera frugiperda cells or Trichoplusia ni cells (cf. US 5,077,214). Culture conditions may suitably be as described in, for instance, WO 89/01029 or 35 WO 89/01028, or any of the aforementioned references.
Transgenic animals It is also within the scope of the present invention to employ transgenic animal technology to produce the present s polypeptide . A transgenic animal is one in whose genome a het erologous DNA sequence has been introduced. In particular, the polypeptide of the invention may be expressed in the mammary glands of a non-human female mammal, in particular one which is known to produce large quantities of milk. Examples of pre-io ferred mammals are livestock animals such as goats, sheep and cattle, although smaller mammals such as mice, rabbits or rats may also be employed.
The DNA sequence encoding the present polypeptide may be introduced into the animal by any one of the methods previously i5 described for the purpose. For instance, to obtain expression in a mammary gland, a transcription promoter from a milk pro-tein gene is used. Milk protein genes include the genes encod-ing casein (cf. US 5,304,489), beta-lactoglobulin, alpha-lactalbumin and whey acidic protein. The currently preferred 2o promoter is the beta-lactoglobulin promoter (cf. Whitelaw et al., Biochem J. 286, 1992, pp. 31-39).
It is generally recognized in the art that DNA sequences lacking introns are poorly expressed in transgenic animals in comparison with those containing introns (cf. Brinster et al., z5 Proc. Natl. Acad. Sci. USA 85, 1988, pp. 836-840; Palmiter et al., Proc. Natl. Acad. Sci. USA 88, 1991, pp. 478-482; Whitelaw et al., Transgenic Res. 1, 1991, pp. 3-13; WO 89/01343; WO
91/02318). For expression in transgenic animals, it is there-fore preferred, whenever possible, to use genomic sequences 3o containing all or some of the native introns of the gene encod-ing the polypeptide of interest. It may also be preferred to include at least some introns from, e.g. the beta-lactoglobulin gene. One such region is a DNA segment which provides for in-tron splicing and RNA polyadenylation from the 3' non-coding 35 region of the ovine beta-lactogloblin gene. when substituted for the native 3' non-coding sequences of a gene, this segment may will enhance and stabilise expression levels of the poly-peptide of interest. It may also be possible to replace the re-gion surrounding the initiation codon of the polypeptide of in-terest with corresponding sequences of a milk protein gene.
s Such replacement provides a putative tissue-specific initiation environment to enhance expression.
For expression of the present polypeptide in transgenic animals, a nucleotide sequence encoding the polypeptide is op-erably linked to additional DNA sequences required for its ex-io pression to produce expression units. Such additional sequences include a promoter as indicated above, as well as sequences providing for termination of transcription and polyadenylation of mRNA. The expression unit further includes a DNA sequence encoding a secretory signal sequence operably linked to the se-i5 quence encoding the polypeptide. The secretory signal sequence may be one native to the polypeptide or may be that of another protein such as a milk protein (cf. von Heijne et al., Nucl.
Acids Res. 14, 1986, pp. 4683-4690; and US 4,873,316).
Construction of the expression unit for use in transgenic 2o animals may conveniently be done by inserting a DNA sequence encoding the present polypeptide into a vector containing the additional DNA sequences, although the expression unit may be constructed by essentially any sequence of legations. It is particularly convenient to provide a vector containing a DNA
as sequence encoding a milk protein and to replace the coding re-gion for the milk protein with a DNA sequence coding for the present polypeptide, thereby creating a fusion which includes expression control sequences of the milk protein gene.
The expression unit is then introduced into fertilized 30 ova or early-stage embryos of the selected host species. Intro duction of heterologous DNA may be carried out in a number of ways, including microinjection (cf. US 4,873,191), retroviral infection (cf. Jaenisch, Science 240, 1988, pp. 1468-1474) or site-directed integration using embryonic stem cells (reviewed 35 by Bradley et al., Bio/Technology 10, 1992, pp. 534-539). The ova are then implanted into the oviducts or uteri of pseudo-pregnant females and allowed to develop to term. Offspring car-rying the introduced DNA in their germ line can pass the DNA on to their progeny, allowing the development of transgenic herds.
General procedures for producing transgenic animals are s known in the art, cf . for instance, Hogan et al . , Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Labo ratory, 1986; Simons et al., Bio/Technology 6, 1988, pp. 179 183; Wall et al., Biol. Reprod. 32, 1985, pp. 645-651; Buhler et al., Bio/Technology 8, 1990, pp. 140-143; Ebert et al., io Bio/Technology 6: 179-183, 1988; Krimpenfort et al., Bio/Technology 9: 844-847, 1991, Wall et al., J. Cell. Biochem.
49: 113-120, 1992; US 4,873,191, US 4,873,316; WO 88/00239, WO
90/05188; WO 92/11757 and GB 87/00458. Techniques for introduc-ing heterologous DNA sequences into mammals and their germ is cells were originally developed in the mouse. See, e.g. Gordon et al., Proc. Natl. Acad. Sci. USA 77: 7380-7384, 1980, Gordon and Ruddle, Science 214: 1244-1246, 1981; Palmiter and Brin-ster, Cell 41: 343-345, 1985; Brinster et al., Proc. Natl.
Acad. Sci. USA 82: 4438-4442, 1985; and Hogan et al. (ibid.).
zo These techniques were subsequently adapted for use with larger animals, including livestock species (see e.g., WO 88/00239, WO
90/01588 and WO 92/11757; and Simons et al., Bio/Technology 6:
179-183, 1988). To summarize, in the most efficient route used to date in the generation of transgenic mice or livestock, sev-2s eral hundred linear molecules of the DNA of interest are in-jected into one of the pro-nuclei of a fertilized egg according to techniques which have become standard in the art . Inj ection of DNA into the cytoplasm of a zygote can also be employed.
3o Transgenic plants Production in transgenic plants may also be employed. It has previously been described to introduce DNA sequences into plants, which sequences code for protein products imparting to the transformed plants certain desirable properties such as in-3s creased resistance against pests, pathogens, herbicides or stress conditions (cf. for instance EP 131 620, EP 205 518, EP
270 355, WO 89/04371 or WO 90/02804), or an improved nutrient value of the plant proteins (cf. for instance EP 90 033, EP 205 518 or WO 89/04371). Furthermore, WO 89/12386 discloses the transformation of plant cells with a gene coding for levansu-s crase or dextransucrase, regeneration of the plant (especially a tomato plant) from the cell resulting in fruit products with altered viscosity characteristics.
In the plant cell, the DNA sequence encoding the present polypeptide is under the control of a regulatory sequence which io directs the expression of the polypeptide from the DNA sequence in plant cells and intact plants. The regulatory sequence may be either endogenous or heterologous to the host plant cell.
The regulatory sequence may comprise a promoter capable of directing the transcription of the DNA sequence encoding the is polypeptide in plants . Examples of promoters which may be used according to the invention are the 35s RNA promoter from cauli-flower mosaic virus (CaMV) , the class I patatin gene B 33 pro-moter, the ST-LS1 gene promoter, promoters conferring seed-specific expression, e.g. the phaseolin promoter, or promoters 2o which are activated on wounding, such as the promoter of the proteinase inhibitor II gene or the wunl or wun2 genes.
The promoter may be operably connected to an enhancer se-quence, the purpose of which is to ensure increased transcrip-tion of the DNA sequence encoding the polypeptide. Examples of as useful enhancer sequences are enhancers from the 5'-upstream region of the 35s RNA of CaMV, the 5'-upstream region of the ST-LS1 gene, the 5'-upstream region of the Cab gene from wheat, the 5'-upstream region of the 1'- and 2'-genes of the TR-DNA of the Ti plasmid pTi ACH5, the 5'-upstream region of the octopine 3o synthase gene, the 5'-upstream region of the leghemoglobin ge-ne, etc.
The regulatory sequence may also comprise a terminator capable of terminating the transcription of the DNA sequence encoding the polypeptide in plants. Examples of suitable termi-35 nators are the terminator of the octopine synthase gene of the T-DNA of the Ti-plasmid pTiACH5 of Agrobacterium tumefaciens, of the gene 7 of the T-DNA of the Ti plasmid pTiACH5, of the nopaline synthase gene, of the 35s RNA-coding gene from CaMV or from various plant genes, e.g. the ST-LS1 gene, the Cab gene s from wheat, class I and class II patatin genes, etc.
The DNA sequence encoding the polypeptide may also be op-erably connected to a DNA sequence encoding a leader peptide capable of directing the transport of the expressed polypeptide to a specific cellular compartment (e.g. vacuoles) or to ex-io tracellular space. Examples of suitable leader peptides are the leader peptide of proteinase inhibitor II from potato, the leader peptide and an additional about 100 amino acid fragments of patatin, or the transit peptide of various nucleus-encoded proteins directed into chloroplasts (e. g. from the St-LS1 gene, i5 SS-Rubisco genes, etc.) or into mitochondria (e.g. from the ADP/ATP translocator).
Furthermore, the DNA sequence encoding the polypeptide may be modified in the 5' non-translated region resulting in enhanced translation of the sequence. Such modifications may, 2o for instance, result in removal of hairpin loops in RNA of the 5' non-translated region. Translation enhancement may be pro-vided by suitably modifying the omega sequence of tobacco mo-saic virus or the leaders of other plant viruses (e. g. BMV, MSV) or of plant genes expressed at high levels (e.g. SS-25 Rubisco, class I patatin or proteinase inhibitor II genes from potato) .
The DNA sequence encoding the polypeptide may furthermore be connected to a second DNA sequence encoding another polypep-tide or a fragment thereof in such a way that expression of 3o said DNA sequences results in the production of a fusion pro-tein. When the host cell is a potato plant cell, the second DNA
sequence may, for instance, encode patatin or a fragment the-reof (such as a fragment of about 100 amino acids).
The plant in which the DNA sequence coding for the poly 3s peptide is introduced may suitably be a dicotyledonous plant, examples of which are a tobacco, potato, tomato, or leguminous (e. g. bean, pea, soy, alfalfa) plant. It is, however, contem-plated that monocotyledonous plants, e.g. cereals, may equally well be transformed with the DNA sequence coding for the en-zyme.
s Procedures for the genetic manipulation of mono-cotyledonous and dicotyledonous plants are well known. In order to construct foreign genes for their subsequent introduction into higher plants, numerous cloning vectors are available which generally contain a replication system for E. coli and a io selectable/screenable marker system permitting the recognition of transformed cells. These vectors include e.g. pBR322, the pUC series, pACYC, M13 mp series etc. The foreign sequence may be cloned into appropriate restriction sites. The recombinant plasmid obtained in this way may subsequently be used for the is transformation of E. coli. Transformed E. coli cells may be grown in an appropriate medium, harvested and lysed. The chi-meric plasmid may then be re-isolated and analyzed. Analysis of the recombinant plasmid may be performed by a . g. determination of the nucleotide sequence, restriction analysis, electrophore-2o sis and other molecular-biochemical methods. After each manipu-lation the sequence may be cleaved and ligated to another DNA
sequence. Each DNA sequence can be cloned on a separate plasmid DNA. Depending on the way used for transferring the foreign DNA
into plant cells other DNA sequences might be of importance. In zs case the Ti-plasmid or the Ri plasmid of Agrobacterium tumefa-ciens or Agrobacterium rhizogenes, at least the right border of the T-DNA may be used, and often both the right and the left borders of the T-DNA of the Ri or Ti plasmid will be present flanking the DNA sequence to be transferred into plant cells.
3o The use of the T-DNA for transferring foreign DNA into plant cells has been described extensively in the prior litera-ture (cf. Gasser and Fraley, 1989, Science 244, 1293 - 1299 and references cited therein). After integration of the foreign DNA
into the plant genome, this sequence is fairly stable at the 3s original locus and is usually not lost in subsequent mitotic or meiotic divisions. As a general rule, a selectable marker gene will be co-transferred in addition to the gene to be trans-ferred, which marker renders the plant cell resistant to cer-tain antibiotics, e.g. kanamycin, hygromycin, 6418 etc. This marker permits the recognition of the transformed cells con-s taming the DNA sequence to be transferred compared to non-transformed cells.
Numerous techniques are available for the introduction of DNA into a plant cell. Examples are the Agrobacterium mediated transfer, the fusion of protoplasts with liposomes containing io the respective DNA, microinjection of foreign DNA, electro-poration etc. In case Agrobacterium mediated gene transfer is employed, the DNA to be transferred has to be present in spe-cial plasmids which are either of the intermediate type or the binary type . Due to the presence of sequences homologous to T-i5 DNA sequences, intermediate vectors may integrate into the Ri-or Ti-plasmid by homologous recombination. The Ri- or Ti-plasmid additionally contains the vir-region which is necessary for the transfer of the foreign gene into plant cells. Interme-diate vectors cannot replicate in Agrobacterium species and are 2o transferred into Agrobacterium by either direct transformation or mobilization by means of helper plasmids (conjugation). (Cf.
Gasser and Fraley, op. cit. and references cited therein).
Binary vectors may replicate in both Agrobacterium spe cies and E. coli. They may contain a selectable marker and a 25 poly-linker region which to the left and right contains the border sequences of the T-DNA of Agrobacterium rhizogenes or Agrobacterium tumefaciens. Such vectors may be transformed di-rectly into Agrobacterium species. The Agrobacterium cell serv-ing as the host cell has to contain a vir-region on another 3o plasmid. Additional T-DNA sequences may also be contained in the Agrobacterium cell.
The Agrobacterium cell containing the DNA sequences to be transferred into plant cells either on a binary vector or in the form of a co-integrate between the intermediate vector and 35 the T-DNA region may then be used for transforming plant cells.
Usually either multicellular explants (e. g. leaf discs, stem segments, roots), single cells (protoplasts) or cell suspen-sions are co-cultivated with Agrobacterium cells containing the DNA sequence to be transferred into plant cells. The plant cells treated with the Agrobacterium cells are then selected s for the co-transferred resistance marker (e.g. kanamycin) and subsequently regenerated to intact plants. These regenerated plants will then be tested for the presence of the DNA se-quences to be transferred.
If the DNA is transferred by e.g. electroporation or mi io croinjection, no special requirements are needed to effect transformation. Simple plasmids e.g. of the pUC series may be used to transform plant cells. Regenerated transgenic plants may be grown normally in a greenhouse or under other condi tions. They should display a new phenotype (e.g. production of i5 new proteins) due to the transfer of the foreign gene(s). The transgenic plants may be crossed with other plants which may either be wild-type or transgenic plants transformed with the same or another DNA sequence. Seeds obtained from transgenic plants should be tested to assure that the new genetic trait is 2o inherited in a stable Mendelian fashion.
See also Hiatt, Nature 344: 469-479, 1990; Edelbaum et al., J. Interferon Res. 12: 449-453, 1992; Sijmons et al., Bio/Technology 8: 217-221, 1990: and EP 255 378.
25 Methods of Production The transformed or transfected host cells described above are cultured in a suitable nutrient medium under conditions permitting the production of the desired molecules, after which these are recovered from the cells, or the culture broth.
3o The medium used to culture the cells may be any conven-tional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements.
Suitable media are available from commercial suppliers or may be prepared according to published recipes (e. g. in catalogues 35 of the American Type Culture Collection). The media are pre-pared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, CA, 1991).
If the molecules are secreted into the nutrient medium, s they can be recovered directly from the medium. If they are not secreted, they can recovered from cell lysates. The molecules are recovered from the culture medium by conventional proce dures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous io components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chroma-tographic procedures, e.g. ion exchange chromatography, gelfil-tration chromatography, affinity chromatography, or the like, dependent on the type of molecule in question.
i5 The molecules of interest may be detected using methods known in the art that are specific for the molecules. These de-tection methods may include use of specific antibodies, forma-tion of a product, or disappearance of a substrate. For exam-ple, an enzyme assay may be used to determine the activity of 2o the molecule. Procedures for determining various kinds of ac-tivity are known in the art.
The molecules of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hy-25 drophobic, chromatofocusing, and size exclusion), electropho-retic procedures (e. g., preparative isoelectric focusing (IEF), differential solubility (e. g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
Detailed description of the invention When cell cultures rather than purified substances are used in assays, a complication arises: Cells, cell particles, growth media or matter secreted by the cells can have an effect on the treatment (e. g., heat treatment) of the substance in question, on the assay itself or on the detection of the assay signal.
The present invention provides solutions to these problems.
As it is not feasible to handle individual clones sepa rately, it also becomes necessary with respect to the assay to s level out differences in growth, gene expression and other dif fering characteristics of individual clones, in order to handle many clones simultaneously in an automated manner.
The present invention solves these problems, by defining conditions of growth so as to achieve a uniform distribution of io growth and gene expression in identical clones in the wells of the same microtiter plate (MTP), or by developing a method for doing HTS-assays that are independent of molecule concentra-tions within a broad range. Solutions to these problems include accurate and simple detection of the concentration of the ac-i5 tive molecules, and development of automated assays that incor-porate this information in the protocol during the assay, or that produce raw-data that can be corrected by use of this in-formation after the assay has been performed.
Altogether, the solutions provided by this invention 2o makes microtiter plate based high throughput screening of sub-stances produced by cell cultures a practical and reliable method for the identification of novel substances with inter-esting properties, from large libraries of molecules.
A first preferred embodiment of the invention relates to 25 a method for high throughput screening (HTS) of a large popula tion of host cells for production of a molecule of interest, the method comprising the steps of:
a) arranging the host cells in a spatial array so each posi-tion in the spatial array is occupied by one cell, 3o b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and d) selecting the cells from those positions where the mole-35 cule was produced, as determined in step c).
A method of the first aspect can be performed in many ways, the spatial array of step a) can take on any physical form whatsoever, that enables the assaying of several samples s at once, without one sample contaminating another. Examples of preferred spatial arrays are different kinds of microtiter-plates with any number of wells, such as 96 or 384, and of any kind of material, as well as positions in a High Performance Liquid Chromatography (HPLC) autosampler device. Any kind of io physical arrangement which allows the unambiguous identifica tion of the samples by a number or a position in the array.
Even samples placed as drops on a surface in a specific re corded pattern, the surface being of a solid material or of more complex nature such as a textile or a tissue, e.g. cotton, i5 wool, paper, or cellulose.
A preferred embodiment relates to a method of the first aspect, wherein the spatial array of point a) is a microtiter plate, a solid surface or a textile surface.
A way of carrying out step c) of the first aspect of the 2o invention could be to take a sample from each position of the spatial array, e.g. from a supernatant or cell, and transfer this to another spatial array for further testing or assaying for production of the molecule of interest (see example 2). The second spatial array may be identical to the first one used in z5 the specific method, but may also be of any other kind that fulfils the above mentioned criteria, such as a microtiter plate, a solid surface, a textile, any material etc.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein after step b) a sample is transferred 3o from each position in the spatial array to a position in a sec ond spatial array which is then used onwards in the method, preferably the second array is a microtiter plate, more pref-erably a solid surface, and most preferably a textile surface.
It is a difficult task to make protein libraries in fila 35 mentous fungi. One problem is that the different morphology and growth rate of different clones give rise to large and small clones that tend to grow out of their position in the spatial array. Assaying fungal transformants of different sizes is also a difficult task due to differences in amounts of produced molecules. The present invention solves this by growing the in-s dividual clones/cells within microenvironments in each position of the spatial array (see example 9). Such microenvironments are initially sterile beads or balls of any material that al-lows growth of the clone, preferably beads comprising agarose, alginate, polysaccharide, carbohydrate, alginate, carrageenan, io chitosan, cellulose, pectin, dextran or polyacrylamide, all al-lowing diffusion to/from each micro-environment.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein each position in the spatial array is occupied by a bead comprising one cell, preferably the bead is is an agarose-bead.
The assaying of the first aspect of the invention for production of the molecule of interest can be done in a great number of ways. As indicated, some kinds of spatial arrays like microtiter plates, can sometimes be assayed directly, or sam-zo ples can be taken from each position and transferred to another spatial array for assaying. The assay as such can be based on a number of techniques well known in the art such as antibody binding, ELISA and many others; common to these assays is that a measurement is taken of a detectable property e.g. fluores-2s cence, luminescence, (3-galactosidase or another enzymatic ac-tivity etc. The method of the invention can be performed with any number of these assays, and consequently the molecules as-sayed for in the first aspect step c) can be obtained in a num-ber of ways, depending on the host cell construct. The molecule 30 of interest may be secreted by the host cell into the super-natant, lysis of the host cells may release the molecule or the molecule may remain intracellular.
A preferred embodiment relates to a method of the first aspect, wherein the molecule of interest in the first aspect step c) is 3s assayed in either whole broth, supernatant of cells that se Crete the molecule, a lysate of cells that produce the mole-cule, or is assayed while still inside cells that produce the molecule.
As described above, any number of host cells can be used s to perform the method of the invention.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the host cells are of mammalian ori-gin, preferably hybridoma cells.
More preferably the host cells are of microbial origin, io preferably bacterial or fungal.
Even more preferably the host cells are chosen from the group consisting of Escherichia coli, Bacillus subtilis, Bacil lus licheniformis, Bacillus clausii, Aspergillus niger, Asper gillus oryzae, Aspergillus nidulans, and Saccharomyces cere i5 visiae.
The molecule of interest in the first aspect of the in-vention can be any molecule of biological origin, non-limiting examples of which are peptides, polypeptides, proteins, en-zo zymes, post-translationally modified polypeptides such as lipopeptides or glycosylated peptides, antimicrobial peptides or molecules, primary or secondary metabolites such as algi-nates, small organic molecules, molecules having pharmaceutical properties etc.
z5 Accordingly a preferred embodiment relates to a method of the first aspect, wherein the molecule of interest is chosen from the group consisting of polypeptides, small peptides, lipopeptides, antimicrobials, small molecules and pharmaceuti-cal molecules.
3o Another preferred embodiment relates to a method of the first aspect, wherein the molecule is an enzyme, preferably chosen from the group consisting of amylase, amyloglucosidase, carbohydrase, carboxypeptidase, cellulase, glucoamylase, glu-cose oxidase, glucosidase, haloperoxidase, hemicellulase, in-35 vertase, isomerase, laccase, lipase, lyase, mannosidase, oxi-dase, pectinolytic enzyme, peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, and transglutaminase.
An obstacle when working with more than one clone is that different clones produce different levels of different vari ants, which means that a quantitative comparison of e.g. mole cule yield between the clones is difficult. The invention pro-vides a way to overcome this obstacle, by growing the clones under conditions that ensure minimal variation in molecule con-centration between the clones. Non-limiting examples of growth io conditions that must be kept essentially equal over the entire spatial array, or similar in each position are temperature, component concentrations in solution (equalize the evaporation from each position, see example 1), amount of molecule produced in each position (see example 9) etc.
is Accordingly a preferred embodiment relates to a method of the first aspect, wherein the growth conditions of the first aspect step b) ensure minimal variation in the molecule concen-tration between all positions in the spatial array.
An obstacle to achieve efficient HTS is how to obtain an 2o accurate determination of the amount of specific active mole cule produced by each individual clone. One solution is to con figure an assay in such a way that it is insensitive to the concentration of the molecule (as exemplified in example 2).
Another solution is that when the concentration of the specific 25 molecule in a position of the spatial array has been deter-mined, this information can be used to determine the specific activity from the total activity determined in that position;
alternatively, the information can be used to adjust the input-amount of the molecule into the activity assay.
3o Non-limiting examples of how the concentration of the specific molecule may be determined are: a) Total molecule measurement. In cases where the molecule of interest is se-creted and makes up a large proportion of the culture super-natant, a total molecule determination will provide a reason-35 able estimate for the amount of specific molecule; b) Specific molecule measurements. The concentration of e.g. a specific molecule such as an enzyme may be determined by any of the fol-lowing methods (see examples):
a.Active site titration of enzymes using a specific enzyme s inhibitor.
b.By using a fluorescently labelled molecule that binds spe cifically to the molecule of interest, and measure the change in fluorescence polarization as the labelled mole cule is added to the culture supernatant containing the io molecule of interest, c. By ELISA measurements using antibodies against the spe-cific protein, including competitive ELISA, d. Co-expression of green fluorescent protein. By transcrip tional (or translational) fusion of a detectable protein i5 (e.g., Green Fluorescent Protein, GFP) and measurement of fluorescense in the enzyme/protein solution, e.Tagging of the enzyme/protein in question, followed by la-belling and subsequent detection (e. g. with fluorescent probe or NMR imaging agent) of the tag.
2o f. Alternatively, the amount of enzyme/protein input into the assay may be controlled (kept constant) by the inclusion of a purification step, e.g. Ni-NTA purification of His-tagged proteins or binding of enzyme/protein to specific antibody.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay of the first aspect step c) is done under conditions where the assay is essentially inde-pendent of the concentration of the molecule.
3o Preferably the molecule is an enzyme, and the enzyme con-centration is in a range of preferably 98% below to 400 % above the average concentration of enzyme employed in the assay, more preferably 50% below to 200% above the average concentration of enzyme employed in the assay.
Another preferred embodiment relates to a method of the first aspect, wherein the assay done in the first aspect step c) is followed by the additional steps of:
a) determining the concentration of the molecule of in-s terest for each position; and b) adjusting the concentration of molecules in each posi-tion to essentially the same level and then performing the assay of the first aspect step c); or c) performing the assay in the first aspect step c) and io then correcting the data obtained with regard to the concentration of the molecule.
Preferably the molecule of interest is an enzyme, and the concentration in step a) of the preceding embodiment is indi-rectly determined by a method chosen from the group consisting is of active site titration using an enzyme inhibitor, measurement of fluorescence polarization using a fluorescently labelled en-zyme inhibitor, measurement of labelled anti-enzyme antibodies, and measurement of a marker protein co-expressed with the en-zyme.
2o An additional preferred embodiment relates to a method of the first aspect, wherein the cultivation of the first aspect step b) is followed by an additional step of recovering from each position essentially the same amount of molecule and using these recovered amounts in the assay of the first aspect step as c) .
Preferably the molecule of the previous embodiment is a polypeptide, and the recovery is achieved by fusing a polyhis-tidine-tag to the polypeptide and recovering this construct on a Ni-NTA solid support.
3o when a screening method is used, the choice of assay de-pends on the molecule of interest and on the host cell con-struct. Many ways are known in the art to assay or monitor the production of a molecule, some in vivo others in vitro. Usually such assays are based on the determination of a chemical or 35 physical event, which may be directly indicative or indirectly through a cascade of events resulting in e.g. a change of col-our in the host cell or in the surrounding medium, emission of light, production of detectable secondary molecules like pro-teins or enzymes, binding of detectable molecules, cell death, cell lysis, cell growth inhibition or promotion (see examples).
s Non-limiting examples of events are:
1. Cleavage or other modification of a substrate in solution.
2. Cleavage or other modification of a substrate (e.g. a stain), covalently or non-covalently attached to textile or other type of solid material, e.g. ceramics, metal surfaces, io plastic or other polymer.
3. Cleavage or other modification of substrate cross-linked/immobilized to bacterial cellulose or other type of polymer surface .
4. Cleavage or other modification of non-stained textile i5 swatches (e. g., cellulose swatch).
5. Interaction with live cells, resulting in lysis, growth in-hibition or growth promotion of these cells.
6. Interaction with another molecule, or group of molecules, leading to a binding event.
ao These events may be detected by e.9. radioactivity, fluo-rescence, fluorescense polarization, luminiscence, NMR, mass spectrometry, absorbance etc. The substance assayed for may be derived from for example cell culture supernatants, lyzed cells or live cells.
25 Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) allows the determination of a chemical or physical event in a live cell, preferably lysis, growth inhibition, growth promotion, production of a protein or another molecule 3o by the cell.
Another preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) allows the determination of an event in which the molecule of interest interacts with another molecule, preferably leading to a binding event or a chemical modification of the other molecule.
Yet another preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect s step c) allows the determination of the cleavage, isomeriza tion, ligation or other modification of a substrate.
Preferably the substrate of the preceding embodiment is a polymer, more preferably chosen from the group consisting of polypeptides, celluloses, polysaccharides, and starches.
io Also, preferably the substrate of the two preceding em-bodiments is immobilized to the surface of a solid material, preferably textile or ceramics.
More preferably the substrate is a solid surface, most preferably a cellulose swatch.
is The substrate of the four preceding embodiments is pref-erably labelled with a detectable probe.
Preferably the probe of the preceding embodiment is fluo-rescent, more preferably it is fluorescein-5-isothiocyanate (FITC) or dichlorotriazino-5-aminofluorescein (DTAF).
2o An industrially very interesting area of research, is the optimization of enzymes to be used in washing applications, consequently the method of the invention is particularly inter-esting in this area of enzyme research. The assay of the first aspect step c) can be carried out under conditions of high pH
is and elevated temperatures by adding detergent, powder or fluid, to the assay and controlling the temperature as well as the shaking.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay of the first aspect step c) 3o is performed in a solution comprising a detergent and where the molecule of interest is an enzyme.
As describe above, a number of assays well known in the art can be used with the present invention, these could be based on any detectable or measurable property that can be as 35 sociated with production of the molecule of interest.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) involves detection of a signal chosen from the group consisting of fluorescence, fluorescence polarization, absorb-s ance, radioactivity, nuclear magnetic resonance (NMR) and luminiscence.
It was mentioned above how varying concentrations of the molecule in the positions of the spatial array could impair the method of the invention, however not only concentration but io also total amount can vary, and measures can be taken to equal-ize total amount produced of the molecule of interest (see ex-amples 4, 5, 7, and 9).
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the growth conditions of the first i5 aspect step b), have been optimized to give minimal variation in the amount produced of the molecule of interest in each po-sition of the spatial array.
A preferred embodiment relates to a method of the first aspect, wherein the growth conditions are chosen so as to mimic 2o the conditions under full-scale fermentations, preferably high ly dilute media are chosen.
A method for screening a DNA library for DNA of interest according to the second aspect of the invention. An essential element in this method is a step of using the method of the 25 first aspect as described herein.
In the art, ways of generating and producing DNA librar-ies from natural sources are well known, but besides natural DNA sequences, a number of ways are also known in which to gen-erate very large populations of diverse artificial DNA se-3o quences starting from one or more natural sequences, e.g. shuf-fling or directed evolution (WO 98/42832; US 5,965,408; WO
98/01581; WO 97/07205; WO 95/22625; US 5,093,257).
A preferred embodiment relates to a method of the second aspect, wherein the DNA library is generated from a natural DNA
35 sequence by DNA shuffling or directed evolution.
Preferably the host cells of the second aspect step a) are of microbial origin.
A recombinant vector according to the third aspect com prising DNA isolated by a method as defined in the second as s pect of the invention.
A recombinant host cell according to the fourth aspect comprising DNA isolated by a method as described in the second aspect or the vector according to the third aspect.
Preferably the cell according to the fourth aspect is of io microbial origin, even more preferably of Bacillus or Aspergil lus origin, and most preferably chosen from the group consist ing of: Escherichia coli, Bacillus subtilis, Bacillus licheni formis, Bacillus clausii, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, and Saccharomyces cerevisiae.
i5 A transgenic animal according to the fifth aspect con-taining and expressing the DNA of interest according to the second aspect.
A transgenic plant according to the sixth aspect containing and expressing the DNA of interest according to the 2o second aspect.
The industrial interest in the method of the invention is of course spurred by the potential of producing the molecule of interest according to the aspects of the invention. Hence the invention relates to the ways known in the art of producing as such molecules as described in more detail above.
A method of producing a molecule of interest according to the seventh aspect, which method comprises cultivating a cell according to the fourth aspect in suitable culture medium under conditions permitting expression of the DNA of interest and so recovering the resulting molecule from the culture medium.
A method of producing a molecule of interest according to the eight aspect, which method comprises recovering the molecule from any part or secrete of/from the transgenic animal according to the fifth aspect.
35 A method of producing a molecule of interest according to the final aspect, which method comprises growing a cell of a transgenic plant according to the sixth aspect, and recovering the molecule from the resulting plant.
Example 1 s Minimization of evaporation of liquids from microtiter-plates by the use of a culture box.
A culture box was designed in order to minimize evapora-tion of liquids from miniaturized microtiter plate fermenta-tions and analytical methods at temperatures from 30-45°C, or io even 4-99°C. The box is designed with a shallow base to hold wa-ter and absorbent paper. A tray is secured to a base that holds stacks of microtiter plates between stainless steel rods. An airtight lid fitted with a silicon gasket is placed over the base/tray and the lid is secured with clamps on all 4 sides.
i5 Rubber bands are placed around each set of 4 rods that are used to secure the plates into position, such that when the box is placed in an incubator shaker the entire device moves as a sin-gle unit.
Use of the culture box eliminates or minimizes many of 2o the problems associated with miniaturized analytical and fer mentation methods in microtiter plates. By limiting evapora tion, the growth and expression differences across the plate, particularly the differences between clones in the centre and at the edges are minimized. It allows a more uniform growth in as static or shaken cultures, as well as allows adequate oxygena-tion of cultures by rapid plate shaking (up to 400 RPM) for several days. The use of this box allows for a wide variety of experimental conditions to be performed in microtiter plates, e.g. , very low volumes (2 - 20 ml in a 96 well plate) and very 3o dilute solutions (media) may be used without significant loss of volume.
Example 2 Wash performance assay for detergent a.-amylase.
Coating of swatches with starch Unmodified starch from a natural source is mixed with small amounts of fluorescently labelled starch and coated on a solid phase. The natural starch source can be flour derived s from e.g. potato, corn, or rice. Especially rice flour has been observed to provide a good correlation to higher scale wash trials. The solid phase may be twill, as twill has been found to provide good correlation to larger scale washes and has good handling properties. The overall starch concentration as well io as the ratio between labelled and unlabeled starch can be var ied over a wide range, but we have found 50 (w/v) unmodified starch and 0.025% (w/v) fluorescin 5-isothiocyanate (FITC) la belled potato starch (50-300 glucose units per FITC molecule) to provide the best compromise between sensitivity and response i5 level (FITC was obtained from Sigma).
The starches are suspended in water and boiled for 10 min, alternatively jet-cooked for 5 min at 105°C and 2 bar. Af-ter cooling, a selected textile is soaked with the cooked sus-pension, excess slurry removed by rolling, and the textile is 2o dried either overnight at ambient temperature or for a few min-utes at high temperature, e.g. 70°C, at high air velocity, e.g.
12 m/s. We have found that automation of this coating procedure to significantly dampen coating variation. By use of a coating machine to continuously coat several hundred meters at a time, as subsequently performed assays with repeated dose-response curves exhibit considerably less variation compared to non-continuous coatings.
Growth of Bacillus cells secreting a-amylase variants 3o Bacillus cells secreting a-amylase variants are grown in 2xYT and 6 ~g/ml Chloramphenicol for three days at 37°C and 240 rpm, in a culture box (see example 1).
High throughput screen for detergent a,-amylases with better 35 wash performance Dry starch coated textile is punched into wells of a polystyrene microtiter plate, preferentially of the 96-well format. Assays are performed by first applying a detergent so-lution, e.g. 150.1, to each well. A range of detergents can be s used such as liquid detergent or powder detergent dissolved in water. water hardness is controlled by the addition of a de-sired amount of calcium and magnesium ions. The assay itself is insensitive to water hardness over a wide range, e.g. 0-30°dH.
If a detergent that contains enzymes is used, these enzymes can io be inactivated by e.g. heating the detergent to 85°C for 5 min prior to the assay. Furthermore, the detergent can be centri fuged and/or filtered before use to minimise particulate mat ter. However, no assay interference due to un-removed particles has been observed with detergents used in the range of dosages i5 recommended by the manufacturers.
The intrinsic pH of detergents can be enforced with buff-ering capacity by adding e.g. glycine or 3-[cyclohexylamino]-1-propane-sulfonic acid (CAPS). This is an important quality en-hancing measure, since the high throughput screen uses culture 2o supernatants as the source of expressed enzyme. Growth media normally contain buffer components to ensure the optimal growth pH, which is rarely equal to the high pH (often pH 9-11) pre-sent in dissolved detergents.
Culture medium from above is added immediately after dis 25 pensing the detergent. We prefer to use a small amount of en zyme solution compared to detergent/buffer, in order to mini mise artefacts caused by e.g. a rich growth medium. For exam ple, we routinely apply 15 ~1 of enzyme solution to 150 ~,l de tergent.
3o Following addition of detergent and enzyme (culture me-dium), the simulated "wash" takes place. Application of me-chanic motion such as vigorous shaking (e. g., 240 rpm) at this point strongly promotes the effect of tested enzymes, thus cre-ating a good dynamic range for ranking candidates. Incubation 3s times at this step from 5 min to 2 h have been tested. When screening for amylases at low-temperature conditions, we have found 15 min "washing" to provide a good window of difference between "good" or "bad" candidates.
Heating can be applied during incubation to simulate the heating of water during machine washing used in many parts of s the world. For example, simulation of European washing condi tions could include heating up to 40 or 60°C. This heating can be introduced gradually by for example placing the ambient tem-perature microtiter tray in a shaking incubator set to the ap-propriate temperature. By this approach, a heat-up profile is io generated. Alternatively, if constant high temperature is de-sired, heated buffers can be added or insulated tubings and thermostated surroundings can be employed.
The assay responses can be read by transferring the wash solution to another microtiter plate and measure released fluo i5 rescence in this solution. Alternatively, the wash solution can be completely removed and the response measured as residual fluorescence of the swatch.
By using the conditions described above, the two ap proaches generate almost exact mirror image data, meaning that ao a high degree of released fluorescence in a well is reflected by a low degree of residual fluorescence on the corresponding swatch and vice versa. We prefer the last method, as this only requires one well per assay, thus ensuring minimal amounts of operations leading to maximal throughput in e.g. a robotic set z s up .
The growth conditions used ensure a reasonably uniform growth of identical clones in different wells of the plate.
However, large differences in expression level between differ-ent variants still exist. V~Ie have found that amylase variants 3o with different performance in the final application release different amounts of fluorescent stain from the swatch in the wash performance assay, even when the enzyme is used in satu-rating concentrations. Therefore, the screen has been set up using very high concentrations of enzyme. Under these condi-35 tions the stain removal efficiency depends only minimally on the enzyme concentration within a broad range; consequently, differences in expression levels between variants have little effect on the performance of the individual variant in the high throughput screening assay.
when applying the assay to libraries of amylase producing s clones, hits are defined as wells of the plate wherein the measurements exceed a given assay response relative to a se lected benchmark amylase.
Results.
io Correlation with the more application-relevant mini-wash test.
Orange coloured rice starch textile was shaken vigorously in 60 mL Asia-Pacific model detergent containing an amylase va-riant, and the reflectance measured. Table 1 below shows the correlation between the performance of three different amylases i5 ( 1, 2 , and 3 ) in the swatch assay ( the High Throughput Screen ing set-up) and the conventional mini-wash test. The improve ment factor in a given assay is given by the performance of the variant amylase divided by the performance of a given benchmark amylase. Obviously, the improved amylase (amylase 3) performs zo better in both the swatch assay and the mini-wash.
Amylase 1 Amylase 2 Amylase 3 Swatch assay 1.0 0.4 1.1 Mini-wash 1.0 0.3 1.3 Table 1: Relative residual fluorescence intensity on washed swathes compared to relative reflectance of orange coloured as rice starch textile in mini wash. Application dosage of 0.2 ~,g/ml amylase was used for the mini wash, while approx. 2 ~g/ml final dosage was used in the swatch assay (the average concen-tration from culture supernatants in the High Throughput As-say) .
Example 3 HTS screening assay for anti-fungal activity An anti-fungal agent can either inhibit the outgrowth of spores, vegetative cells, or both. To identify an anti-fungal agent inhibiting vegetative cells, 50 ~1 samples of a liquid culture of a tester strain, e.g. Botrytis cinerae, are distrib-s uted into each well of a microtiter plate; 50 ~l of samples of sterile culture supernatants from cultures of bacterial cells, e.g. Bacillus, to be screened for secretion of anti-fungal ac-tivities (e. g. variants of an antimicrobial peptide or enzyme), are then added to each well of the microtiter plate. Option-io ally, instead of sterilizing the culture supernatants, a tissue culture insert (e. g., Nunc TC Insert) may be inserted, to pre-vent contact between the secreting cells and cells of the tester strain. The insert may contain a membrane non-permeable to proteins or other macromolecular components, which allows is the passage of for example small antimicrobial peptides. The microtiter plate is incubated at 30°C for 2-5 days whereafter anti-fungal activity is analysed by optical density measure ments in each well at a suitable wavelength. Low optical den sity indicates the presence of an anti-fungal activity in the 2o well .
Example 4 Use of very dilute media for HTS screening of enzyme-secreting fungi for improved yield.
25 In order to mimic the nutrient limiting conditions of fermentor tanks used for production of for example enzymes, mi-crotiter plate-based screens for improved yield are done in di-lute growth media. The dilution ensures that the nutrients, rather than the oxygen, become the growth limiting factors.
3o This allows a simplification in the handling of the assay since the dilute substrate can be added directly to the cultures, be-cause the effects of the media on the assay will be very weak.
35 Example 5 Use of very dilute media for HTS screening of enzyme-secreting fungi for improved expression General HTS set up for yield mutant screening.
s Mutant libraries of Aspergillus oryzae or Aspergillus niger strains are screened by HTS to identify mutants having increased expression, i.e. improved yield of an enzyme. Better yield mutants expressing for example peroxidase, laccase, lipase, glucose oxidase, amylase, xylanase, phytase, and io aminopeptidase have been identified this way.
For 96-well plate screens, very dilute medium containing 100 - 300 mg/1 carbon-source, ensures carbon-limitation without oxygen limitation.
Primary 96-well plate screens involve the dilution of i5 spores from distinct mutant pools into fermentation substrate so that one spore in average is inoculated per well when 1001 of medium is dispensed into each well. After inoculation, the plates are incubated for 3-4 days at 30-34°C under static con ditions in a culture box (see example 1). The wells are then 2o assayed for enzyme activity, for example by the addition of a substrate solution directly to the growth wells.
Mutants of interest are isolated and single colonies transferred to agar slants. Spores from agar slants are inocu-lated into 96-well plates with approx. 103 spores per well and 25 fermented under static conditions for 4 days at 34°C to retest isolates. Subsequently, selected isolates are tested in shake flask fermentations.
Isolation of mutants having increased Shearzyme~ expression 3o An Aspergillus oryzae transformant MT2181 expressing re-combinant Shearzyme~, was mutated by using UV-irradiation. The MT2181 mutant library was fermented in SH-CDY substrate (pH
6.5) in 96 wells plates as described above. The SH-CDY sub-strate contained pr litre : 0 . 3 g MgS04, 7H20, 0 . 3 g KzS04, 5 . 0 g 35 KHzP04, 0.1 ml tracemetal solution, 0.013 g urea, 0.010 g yeast extract, and 0.1 g maltose. The tracemetal solution contains pr litre: 13.8 g FeS04, 7H20, 8.5 g MnS04, HZO, 14.3 g ZnS04, 7 H20, CuS04, 5 HZO, NiCl2, 6 HZO, 3 g citric acid.
Cultures were then assayed for increased yield, i.e. in-s creased Shearzyme~ activity. Shearzymeo, which is an endoxy-lanase, could be quantitated by using a microtiter plate assay and p-nitrophenyl-(3-D-xylopyranoside (Sigma N-2132) as sub-strate, since the enzyme possesses some exo activity, and yel-low p-nitrophenol was generated. A 100 mg/ml p-nitrophenyl-(3-D-io xylopyranoside stock solution was prepared in DMSO. Subse quently, working substrate was prepared by diluting the stock 10 folds in 0.1 M phosphate buffer (pH 6.0). Standard Shearzyme (BioFeed~ (S), Novo Nordisk A/S, Bagsvaerd, Denmark) was prepared so as to contain 20 FXU/ml in 0.1 M phosphate buffer, pH 6Ø
i5 The standard was stored at -20°C until use. Shearzyme~ stock was diluted appropriately to obtain a standard series ranging from 0.1 to 5.0 FXU/ml just before use. 25 ~,1 samples were dispensed to wells in 96-well plates followed by 120 ~.l of substrate by using a robotic set up. Using a plate reader, the absorbance at zo 405 nm was recorded as the difference of two readings taken at approximately 4 minutes intervals. Shearzyme~ units/ml (FXU/ml) were calculated relative to the Shearzyme~ standards.
In the 96-well primary screen followed by the re-test in z5 96-well plates, 9 mutants from the "MT2181 mutant library" were selected. These mutants produced higher yields of Shearzyme~
than the control strain Aspergillus oryzae MT2181. The 4 Shear-zyme~ producing mutants with highest yields were evaluated in shake flasks. The results obtained are shown in table 2 below 3o where the Shearzyme~ yield of A, oryzae MT2181 as a control is normalized to 100.
96-well re-test Shake flask Strain # (FXU/ml) (FXU/ml) MT2181-6-Ol 126 130 Table 2. Shearzyme expression by Mw~l~l inutanzs As shown in table 2, the 4 selected mutants produce ap proximately 20-30 % more Shearzyme~ than the control strain A.
s oryzae MT2181, when fermented in shake flasks.
Example 6 Screening for cellulase activity using Dichlorotriazino-5-aminofluorescein (DTAF) labelled cotton Swatches.
io Preparation of Cotton swatches Style 400 cotton (Center for Test Materials, PO Box 120, 3130 AC Vlowdingen, Holland) was cut to appropriate sizes. The cotton swatches were swollen in a 0.1 N NaOH solution for 24 is hrs. prior to the labelling in order to enhance the accessibil-ity of the hydroxylic groups to the probe. DTAF dissolved in 0.1 N NaOH was added to the swollen swatches, and the reaction mixture was allowed to react for 24 hrs. at room temperature in the dark on a celloshaker-board. The labelled swatches were 2o washed several times using 0.1 N NaOH, water, MeOH, and finally water again. After the last wash-cycle no probe could be found in the supernatant. The swatches were finally dried. The la belled cotton swatches have a clear yellow colour. Further the DTAF-probe makes the swatches highly fluorescent at the 485/518 2s (excitation/emission) wavelength bands.
Similar fluorescence measurements were obtained whether cotton was labelled in swatches of 5-11 g or whether it had been cut into swatches of approx. 3 mg, suitable for subsequent microtiter plate analysis.
Specific release of fluorescence by incubation of DTAF labelled cotton swatches with purified cellulases Labelled swatches were distributed in each well of a 96 well microtiter plate, washed in deionized water, and incubated with 50 ~,1 cellulase enzyme solution and 150 ~1 buffer for 2h, at 40°C, 400 rpm. The microtiter plates were centrifuged at 2800 rpm and fluorescence intensity (485/518 nm) was measured on 150 ~1 of the supernatant, using a spectrophotometer. The cellu-io lases used were endoglucanase (EG) v, EGV-core, EG I, and CBH
II from Humicola insolens (prepared as described in M.
Schiilein, J. Biotechnology, vol 57, pp. 71-81, 1997).
Table 3 shows that EG V performs much better per endocel lulase activity unit than EG I, EG V-Core or CBH II. This is i5 consistent with the performance of these enzymes in multi-wash experiments to determine their effect. Hence, DTAF-swatches can be used to assay cellulases and the results correlate with the performance of the cellulase in performing a full-scale wash experiments.
2o Further, the signal-to-noise ratio is improved by pre-washing the cotton twenty times in a laundry machine, using ei-ther water or a model detergent, before labelling. Also, the signal-to-noise ratio is improved by increasing the number of labelling cycles.
cellulase EG V
units/ml CBH II EG I EG V core 0,0 24,8 29,0 32,6 29,6 0,9 27,2 33,6 37,7 29,7 2,8 24,5 39,2 37,0 29,7 8,0 21,6 39,4 49,3 32,8 25,0 23,8 50,7 70,2 36,4 75, 0 1 36, 1 57, 6 1 112, 1 61, Table 3. Performance of 4 cellulases in the swatch assay ex-pressed as fluorescence intensity in arbitrary units (example 6) .
s High throughput screening for cellulase activities in cell cul-ture supernatants Recombinant H.insolens cellulase VI (W09901544) was ex-pressed in yeast cells (S.cerevisiae, YNG318) using standard methodologies (Sambrook et al.: "Molecular Cloning. A Laboratory io Manual", Cold Spring Harbor, NY,1989). Transformed cells were grown in SC-ura- media for 3 days at 30°C. 100~.L culture super-natant was transferred to an assay plate containing labelled cellulose swatches as described above. After an appropriate time of incubation the well supernatants were transferred to an is assay plate, and the fluorescence was measured. A control ex periment was performed in 0,2M tris buffer at pH 7 employing 100 ~1 supernatant from yeast cultures expressing either recom binant active cellulase EGVI, or an inactive variant of EGVI.
Clones expressing active cellulases gave rise to higher levels 20 of fluorescence than clones expressing the inactive variant:
EGVI(active): 47.8 +/- 1.1 (n=6) EGVI(inactive): 77.7 +/- 1.9 (n=6) 25 The DTAF labelled cotton swatches can also be used in a cell culture-based screen for active cellulases in a high-throughput format: Yeast cells expressing cellulases are sus-pended in minimal media, and aliquoted into 96 well plates at an average of about 30 wells with growth per 96 well plate (to 30 obtain predominantly single cell isolates). After 3 days of growth at 30°C, 100~L culture supernatant is transferred to an assay plate containing cellulose swatches as described above.
Optionally, a well insert (e.g., Nunc TC Insert) may be in-serted, to separate yeast cells and the cellulose swatch. The 35 insert should contain a membrane permeable to the cellulase en-zyme but not to the cells. After an appropriate time of incuba tion, the well supernatants (without any prior centrifugation) are transferred to an empty assay plate, and the fluorescence is measured for each well. Clones expressing active cellulases s give rise to higher levels of fluorescence.
Example 7 His-tagging/purification of proteases to achieve equal protein input from differentially expressing clones.
io The DNA sequence encoding the protease Savinase~ (Novo Nordisk A/S, Denmark) is translationally fused to a sequence encoding a His6 tag and libraries of Savinase~-His6 variants are produced and introduced into Bacillus. After standard growth, a limited number of Savinase~ enzymes of each variant (about 100 i5 of what is secreted by Bacillus carrying the wildtype Savinase gene) are immobilized in the wells of Ni-NTA microtiter plates.
The unbound fraction including cells and excess Savinase~ is re-moved, the plate washed once or twice in a buffer containing 5-20 mM Imidazole. The His-tagged Savinase~ variants are released zo from the solid support by the addition of 250 mM Imidazole, and aliquots of the supernatants from each well are used as input in a wash performance assay as described in the previous exam-ples.
z5 Example 8 Determination of Savinase~ concentration by fluorescence polari-zation measurements.
The CI-2 protease inhibitor is labelled by standard means with a fluorescent probe. After growth as described above, the 3o amount of a Savinase~ variant in a given well may be measured directly in the wells by addition of fluorescence-labelled in-hibitor which upon binding to the protease changes rotational speed. The rotational speed may be monitored by fluorescence polarization analysis or by other means which monitors diffu-35 sion (e.g. fluorescence correlation spectroscopy). Since the amount of Savinase~ variant may vary significantly between the individual wells, the fluorescently labelled CI-2 inhibitor is added in two or three steps of defined amounts and the fluores-cence polarisation is measured after each CI-2 addition. The determined concentration of Savinase~ variant in the individual s well may be used to adjust the input volume from this well into the activity assay, or can be used to correct the obtained ac-tivity data, in order to determine the specific activity of the Savinase~ variant of that well.
io Example 9 High throughput screening in filamentous fungi It is a difficult task to make protein libraries in fila-mentous fungi. One problem is the different morphology and growth rate of different clones. This gives rise to large and i5 small clones, as well as clones that might be outcompeted by other clones. Assaying fungal transformants of different sizes is also a difficult task due to differences in amounts of ex-pressed enzymes. Another problem is the handling of all the clones on the plate.
2o These problems can be overcome by growing the individual clones in alginate balls with a high molecular weight (HMW) dextran as carbon source, and then using the~balls as the sour ce of clonal cell cultures in a microtiter plate . The HMW dex tran lets the slow-growing transformants outgrow, without cross z5 contamination from faster growing transformants.
A Polymerase chain reaction, using pAHL (carrying a Li-pase gene) as the template and 2 pmol/ml of each primer: oligo 115120: (GCTTTGTGCAGGGTAAATC), and oligo 134532: (GAGCAATAT-CAGGCCGCGCACG) is run under the following conditions: 94°C, 5 3o min.; 30 cycles of (94°C, 30 sec.; 50°C, 30 sec.;
72°C, 1 min.), and 72°C, 5 min. and a commercial Taq polymerase, such as Am-pliTaq, (Perkin-Elmer Corp., Branchburg NJ, USA). For example, the PCR conditions 'may result in a high rate of error, and therefore a library of Lipase mutants are generated.
35 Protoplasts of the filamentous fungi strain JaL250 is transformed using 2~.g of pENI1298, which had been digested with Ball and SgrAl to remove most of the lipase encoding sequence, and 5~,g of the above PCR product . The vector and the PCR frag-ment are allowed to recombine in vivo as described in WO
97/07205.
s The protoplasts are washed twice with ST (0.6M sorbitol, 100mM TRIS pH7.0) in order to remove CaCl2. The protoplasts are then re-suspended in an alginate solution (1.5% alginate, 2 0 high molecular weight dextran (5-40*106 kd), 1.2 M sorbitol, 10 mM TRIS pH7.5) . Using a pump, the suspension is pumped through io a small nozzle where small suspension droplets are made. These drops fall down (15 cm) into a shake flask (500m1) containing 0.2M CaCl2, 1.2 M sorbitol, 10 mM TRIS pH7.5. Droplets of an al-ginate solution (typically 1-2 %) turn into hard balls when they encounter a CaClz solution (such as a 0.2 M solution).
i5 Small alginate balls of the size 2.5 mm in diameter are gener-ated by this procedure. The protoplast suspension should be made so that approximately 1 out of 5 balls contains a trans-formed protoplast, in order to avoid multiple clones in the same ball.
zo The protoplast-containing alginate balls are grown over-night at 30°C degrees in STC (10 mM CaCl2, 1.2 M sorbitol, 10 mM
TRIS pH7.5) in order to regenerate the cell wall. After a cou-ple of washes in sterile water to remove sorbitol, the balls are transferred to 1* Vogel media and grown 2-3 days at 30°C de-25 grees. The sole carbon source is the dextran in the balls. This prevents cross-contamination from ball to ball, and allows slow-growing transformants to gain reasonable biomass.
The alginate balls are transferred to a microtiter plate;
one ball into each microtiter well. Liquid growth media is 3o added to the wells and after a period of growth incubation, the growth media is analyzed for lipase activity under the desired conditions.
Perbal, A Practical Guide To Molecular Cloning (1984).
Isolated: When applied to a protein, the term "isolated" indi-Gates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue.
In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal ori-gin. It is preferred to provide the proteins in a highly puri-io fied form, i.e., greater than 95o pure, more preferably greater than 99% pure. When applied to a polynucleotide molecule, the term "isolated" indicates that the molecule is removed from its natural genetic milieu, and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use i5 within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Iso-lated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, and may in-2o clude naturally occurring 5' and 3' un-translated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316: 774-78, 1985).
25 A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or pre-pared from a combination of natural and synthetic molecules.
A "nucleic acid molecule" refers to the phosphate ester poly-meric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (de-oxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine;
"DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA
helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term s includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e. g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular dou-ble-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence io in the 5' to 3' direction along the non-transcribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.
i5 A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a zo translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic se-quences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA se-quences. If the coding sequence is intended for expression in a 25 eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
Expression vector: A DNA molecule, linear or circular, that 3o comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcrip-tion. Such additional segments may include promoter and termi-nator sequences, and optionally one or more origins of replica-tion, one or more selectable markers, an enhancer, a polyade-3s nylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.
Transcriptional and translational control sequences are DNA
s regulatory sequences, such as promoters, enhancers, termina-tors, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.
io A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide" that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory i5 peptide during transit through the secretory pathway.
The term "promoter" is used herein for its art-recognized mean-ing to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of zo transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.
"Operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert 2s for their intended purposes, e.g. transcription initiates in the promoter and proceeds through the coding segment to the terminator.
A coding sequence is "under the control" of transcriptional and 3o translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the cod-ing sequence.
35 "Isolated polypeptide": is a polypeptide which is essentially free of other non-[enzyme] polypeptides, e.g., at least about 20% pure, preferably at least about 40e pure, more preferably about 60% pure, even more preferably about 80% pure, most pref-erably about 90% pure, and even most preferably about 95°s pure, as determined by SDS-PAGE.
"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the he-terologous DNA includes a gene foreign to the cell.
io A cell has been "transfected" by exogenous or heterologous DNA
when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. Preferably, the transforming DNA should be integrated (covalently linked) into i5 chromosomal DNA making up the genome of the cell.
A "clone" is a population of cells derived from a single cell or common ancestor by mitosis.
20 "Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vec-tor targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to 2s sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.
3o Nucleic Acid Sequence The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and in-clude isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic acid sequences 35 of the present invention from such genomic DNA can be effected, e.g., by using the well-known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., In-nis et al., 1990, A Guide to Methods and Application, Academic Press, New York. Other nucleic acid amplification procedures s such as ligase chain reaction (LCR), ligated activated tran-scription (LAT) and nuceic acid sequence-based amplification (NASBA) may be used. The nucleic acid sequence may be cloned from a strain. producing the polypeptide, or from another re-lated organism and thus, for example, may be an allelic or spe-io cies variant of the polypeptide encoding region of the nucleic acid sequence.
The term "isolated" nucleic acid sequence as used herein refers to a nucleic acid sequence which is essentially free of other nucleic acid sequences, e.g., at least about 20o pure, i5 preferably at least about 40% pure, more preferably about 60%
pure, even more preferably about 80o pure, most preferably about 90% pure, and even most preferably about 95o pure, as de-termined by agarose gel electorphoresis. For example, an iso-lated nucleic acid sequence can be obtained by standard cloning zo procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment com-prising the nucleic acid sequence encoding the polypeptide, in-25 sertion of the fragment into a vector molecule, and incorpora-tion of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be repli-cated. The nucleic acid sequence may be of genomic, cDNA, RNA, semi-synthetic, synthetic origin, or any combinations thereof.
Nucleic Acid Construct As used herein the term "nucleic acid construct" is in tended to indicate any nucleic acid molecule of cDNA, genomic DNA, synthetic DNA or RNA origin. The term "construct" is in tended to indicate a nucleic acid segment which may be single or double-stranded, and which may be based on a complete or partial naturally occurring nucleotide sequence encoding a po lypeptide of interest. The construct may optionally contain s other nucleic acid segments.
The DNA of interest may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridization using synthetic oligonucleotide io probes in accordance with standard techniques (cf. Sambrook et al., supra).
The nucleic acid construct may also be prepared syntheti-cally by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters i5 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. According to the phos-phoamidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and clo-ned in suitable vectors.
2o Furthermore, the nucleic acid construct may be of mixed synthetic and genomic, mixed synthetic and cDNA or mixed ge nomic and cDNA origin prepared by ligating fragments of syn thetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various parts of the entire nucleic acid con 25 struct, in accordance with standard techniques.
The nucleic acid construct may also be prepared by poly-merase chain reaction using specific primers, for instance as described in US 4, 683, 202 or Saiki et al . , Science 239 (1988) , 487 - 491.
3o The term nucleic acid construct may be synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term "coding se-quence" as defined herein is a sequence which is transcribed 35 into mRNA and translated into a polypeptide of the present invention when placed under the control of the above mentioned control sequences. The boundaries of the coding sequence are generally determined by a translation start codon ATG at the 5'-terminus and a translation stop codon at the 3'-terminus. A
coding sequence can include, but is not limited to, DNA, cDNA, s and recombinant nucleic acid sequences.
The term "control sequences" is defined herein to include all components which are necessary or advantageous for expres-sion of the coding sequence of the nucleic acid sequence . Each control sequence may be native or foreign to the nucleic acid io sequence encoding the polypeptide. Such control sequences in-clude, but are not limited to, a leader, a polyadenylation se-quence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control se-quences include a promoter, and transcriptional and transla-i5 tional stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction si-tes facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypep-tide.
2o The control sequence may be an appropriate promoter se-quence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control se-quences which mediate the expression of the polypeptide. The 25 promoter may be any nucleic acid sequence which shows tran-scriptional activity in the host cell of choice and may be ob-tained from genes encoding extracellular or intracellular poly-peptides either homologous or heterologous to the host cell.
The control sequence may also be a suitable transcription so terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
35 The control sequence may also be a polyadenylation se-quence, a sequence which is operably linked to the 3' terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in s the present invention.
The control sequence may also be a signal peptide-coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the ex-pressed polypeptide into the cell's secretory pathway of the io host cell. The 5' end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide-coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted poly-peptide. Alternatively, the 5' end of the coding sequence may i5 contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted poly-peptide. A foreign signal peptide-coding region may be required where the coding sequence does not normally contain a signal peptide-coding region. Alternatively, the foreign signal pep-ao tide coding region may simply replace the natural signal pep-tide coding region in order to obtain enhanced secretion rela-tive to the natural signal peptide coding region normally asso-ciated with the coding sequence. The signal peptide-coding re-gion may be obtained from a glucoamylase or an amylase gene is from an Aspergillus species, a lipase or proteinase gene from a Rhizomucor species, the gene for the alpha-factor from Sac-charomyces cerevisiae, an amylase or a protease gene from a Ba-cillus species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed 3o polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.
The control sequence may also be a propeptide coding re-gion, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is 35 known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be con-verted to mature active polypeptide by catalytic or autocata-lytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the Bacillus sub-tilis alkaline protease gene (aprE), the Bacillus subtilis neu-tral protease gene (nprT), the Saccharomyces cerevisiae alpha-factor gene, or the Myceliophthora thermophilum laccase gene (WO 95/33836).
The nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode io one or more factors that are advantageous in the expression of the polypeptide, e.g., an activator (e. g., a trans-acting fac-tor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention. The nucleic acids encoding one or more of is these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.
An activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla et al., 1990, EMBO Journal 9:1355-1364; Jarai and Buxton, 1994, 2o Current Genetics 26:2238-244; Verdier, 1990, Yeast 6:271-297).
The nucleic acid sequence encoding an activator may be obtained from the genes encoding Bacillus stearothermophilus NprA
(nprA), Saccharomyces cerevisiae heme activator protein 1 (haply, Saccharomyces cerevisiae galactose metabolizing protein 25 4 (gal4), and Aspergillus nidulans ammonia regulation protein (areA). For further examples, see Verdier, 1990, supra and MacKenzie et al., 1993, Journal of General Microbiology 139:2295-2307.
A chaperone is a protein which assists another polypep 3o tide in folding properly (Hartl et al., 1994, TIBS 19:20-25;
Bergeron et al., 1994, TIBS 19:124-128; Demolder et al., 1994, Journal of Biotechnology 32:179-189; Craig, 1993, Science 260:1902-1903; Gething and Sambrook, 1992, Nature 355:33-45;
Puig and Gilbert, 1994, Journal of Biological Chemistry 35 269:7764-7771; Wang and Tsou, 1993, The FASEB Journal 7:1515-11157; Robinson et al., 1994, Bio/Technology 1:381-384). The nucleic acid sequence encoding a chaperone may be obtained from the genes encoding Bacillus subtilis GroE proteins, Aspergillus oryzae protein disulphide isomerase, Saccharomyces cerevisiae s calnexin, Saccharomyces cerevisiae BiP/GRP78, and Saccharomyces cerevisiae Hsp70. For further examples, see Gething and Sam-brook, 1992, supra, and Hartl et al., 1994, supra.
A processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypep io tide (Enderlin and Ogrydziak, 1994, Yeast 10:67-79; Fuller et al., 1989, Proceedings of the National Academy of Sciences USA
86:1434-1438; Julius et al., 1984, Cell 37:1075-1089; Julius et al., 1983, Cell 32:839-852). The nucleic acid sequence encoding a processing protease may be obtained from the genes encoding i5 Aspergillus niger Kex2, Saccharomyces cerevisiae dipepti-dylaminopeptidase, Saccharomyces cerevisiae Kex2, and Yarrowia lipolytica dibasic processing endoprotease (xpr6).
It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide 2o relative to the growth of the host cell. Examples of regula tory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
Regulatory systems in prokaryotic systems would include the z5 lac, tac, and trp operator systems . In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA al-pha-amylase promoter, Aspergillus niger glucoamylase promoter, and the Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences 3o are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metal lothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide 35 would be placed in tandem with the regulatory sequence.
Promoters Examples of suitable promoters for directing the tran-scription of the nucleic acid constructs of the present inven tion, especially in a bacterial host cell, are the promoters obtained from the E. coli lac operon, the Streptomyces coeli color agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus subtilis alkaline protease gene, the Bacillus licheniformis alpha-amylase gene (amyl), the Bacillus io stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), the Bacillus amy-loliquefaciens BAN amylase gene, the Bacillus licheniformis pe-nicillinase gene (penP), the Bacillus subtilis xylA and xylB
genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff i5 et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA
80:21-25) , or the Bacillus pumilus xylosidase gene, or by the phage Lambda PR or PL promoters or the E. coli lac, ~ or tac 2o promoters. Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.
Examples of suitable promoters for directing the tran scription of the nucleic acid constructs of the present inven 25 tion in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhi-zomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, As-pergillus niger or Aspergillus awamori glucoamylase (glaA), 3o Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusarium oxysporum trypsin-like protease (as described in U.S. Patent No. 4,288,627, which is incorpo-rated herein by reference), and hybrids thereof. Particularly 35 preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral a-amylase and As-pergillus oryzae triose phosphate isomerase), and glaA promot-ers. Further suitable promoters for use in filamentous fungus s host cells are the ADH3 promoter (McKnight et al . , The EMBO J.
4 (1985), 2093 - 2099) or the t~iA promoter.
Examples of suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255 (1980), 12073 - 12080; Alber and Ka-io wasaki, J. Mol. Appl. Gen. 1 (1982), 419 - 434) or alcohol de-hydrogenase genes (Young et al., in Genetic Engineering of Mi-croorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4,599,311) or ADH2-4c (Russell et al., Nature 304 (1983), 652 - 654) promoters.
i5 Further useful promoters are obtained from the Saccharo-myces cerevisiae enolase (ENO-1) gene, the Saccharomyces cere-visiae galactokinase gene (GAL1), the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the Saccharomyces cerevisiae 3-zo phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8:423-488. In a mammalian host cell, useful promoters include viral promoters such as those from Simian Virus 40 (5V40) , Rous sar-coma virus (RSV), adenovirus, and bovine papilloma virus (BPV).
Examples of suitable promoters for directing the tran scription of the DNA encoding the polypeptide of the invention in mammalian cells are the SV40 promoter (Subramani et al., Mol. Cell Biol. 1 (1981), 854 -864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222 (1983), 809 - 814) or the adenovirus 2 major late promoter.
An example of a suitable promoter for use in insect cells is the polyhedrin promoter (US 4,745,051; Vasuvedan et al., FEBS Lett. 311, (1992) 7 - 11) , the P10 promoter (J.M. Vlak et al., J. Gen. Virology 69, 1988, pp. 765-776), the Autographa californica polyhedrosis virus basic protein promoter (EP 397 485), the baculovirus immediate early gene 1 promoter (US
5,155,037; US 5,162,222), or the baculovirus 39K delayed-early gene promoter (US 5,155,037; US 5,162,222).
s Terminators Preferred terminators for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA
amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and io Fusarium oxysporum trypsin-like protease for fungal hosts) the TPIl (Alber and Kawasaki, ~ cit.) or ADH3 (McKnight et al., op. cit.) terminators.
Preferred terminators for yeast host cells are obtained from the genes encoding Saccharomyces cerevisiae enolase, Sac is charomyces cerevisiae cytochrome C (CYC1), or Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other use-ful terminators for yeast host cells are described by Romanos et al., 1992, supra.
2o Polyadenylation Signals Preferred polyadenylation sequences for filamentous fun gal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergil lus nidulans anthranilate synthase, and Aspergillus niger al 25 pha-glucosidase.
Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Molecular Cellular Biology 15:5983-5990.
Polyadenylation sequences are well known in the art for 3o mammalian host cells such as SV40 or the adenovirus 5 Elb re gion.
Signal Sequences An effective signal peptide-coding region for bacterial 35 host cells is the signal peptide-coding region obtained from the maltogenic amylase gene from Bacillus NCIB 11837, the Ba cillus stearothermophilus alpha-amylase gene, the Bacillus licheniformis subtilisin gene, the Bacillus licheniformis beta-lactamase gene, the Bacillus stearothermophilus neutral prote-ases genes (nprT, nprS, nprM), and the Bacillus subtilis PrsA
s gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from Aspergillus oryzae TAKA amylase gene, Aspergillus niger io neutral amylase gene, the Rhizomucor miehei aspartic proteinase gene, the Humicola lanuginosa cellulase or lipase gene, or the Rhizomucor miehei lipase or protease gene, Aspergillus sp. amy-lase or glucoamylase, a gene encoding a Rhizomucor miehei li-pase or protease. The signal peptide is preferably derived from i5 a gene encoding A. oryzae TAKA amylase, A. niger neutral a-amylase, A. niger acid-stable amylase, or A. niger glucoamy-lase.
Useful signal peptides for yeast host cells are obtained 2o from the genes for Saccharomyces cerevisiae a-factor and Sac-charomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
For secretion from yeast cells, the secretory signal se quence may encode any signal peptide which ensures efficient 25 direction of the expressed polypeptide into the secretory path way of the cell. The signal peptide may be naturally occurring signal peptide, or a functional part thereof, or it may be a synthetic peptide. Suitable signal peptides have been found to be the a-factor signal peptide, the signal peptide of mouse 3o salivary amylase (cf . O. Hagenbuchle et al . , Nature 289, 1981, pp. 643-646), a modified carboxypeptidase signal peptide (cf.
L.A. Valls et al . , Cell 48, 1987, pp. 887-897) , the yeast BAR1 signal peptide (cf. WO 87/02670), or the yeast aspartic prote ase 3 (YAP3) signal peptide (cf. M. Egel-Mitani et al., Yeast 35 6, 1990, pp. 127-137).
For efficient secretion in yeast, a sequence encoding a leader peptide may also be inserted downstream of the signal sequence and upstream of the DNA sequence encoding the polypep-tide. The function of the leader peptide is to allow the ex-pressed polypeptide to be directed from the endoplasmic reticu-lum to the Golgi apparatus and further to a secretory vesicle for secretion into the culture medium (i.e. exportation of the polypeptide across the cell wall or at least through the cellu-lar membrane into the periplasmic space of the yeast cell). The io leader peptide may be the yeast a-factor leader (the use of which is described in e.g. US 4,546,082, EP 123 294, EP 123 544 and EP 163 529). Alternatively, the leader peptide may be a synthetic leader peptide, which is to say a leader peptide not found in nature. Synthetic leader peptides may, for instance, i5 be constructed as described in WO 89/02463 or WO 92/11378.
For use in insect cells, the signal peptide may conven-iently be derived from an insect gene (cf. WO 90/05783), such as the lepidopteran Manduca sexta adipokinetic hormone precur-sor signal peptide (cf. US 5,023,328).
Expression Vectors The present invention also relates to recombinant expres sion vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient re-striction sites to allow for insertion or substitution of the 3o nucleic acid sequence encoding the polypeptide at such sites.
Alternatively, the nucleic acid sequence of the present inven-tion may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appro-priate vector for expression. In creating the expression vec-tor, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.
The recombinant expression vector may be any vector (e. g., a plasmid or virus) which can be conveniently subjected s to recombinant DNA procedures and can bring about the expres sion of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector io may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a mini-chromosome, or an artificial chromosome. The vector may contain any means for assuring self-i5 replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosomes) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together zo contain the total DNA to be introduced into the genome of the host cell, or a transposon.
The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of z5 which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers which confer an-tibiotic resistance such as ampicillin, kanamycin, chloram-3o phenicol, tetracycline, neomycin, hygromycin or methotrexate resistance. A frequently used mammalian marker is the dihydro-folate reductase gene (DHFR). Suitable markers for yeast host cells are ADE2 , HIS3 , LEU2 , LYS2 , MET3 , TRPl , and URA3 . A se-lectable marker for use in a filamentous fungal host cell may 35 be selected from the group including, but not limited to, amdS
(acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phos-photransferase), niaD (nitrate reductase), pyre (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC
(anthranilate synthase), and glufosinate resistance markers, as s well as equivalents from other species. Preferred for use in an Aspergillus cell are the amdS and pyre markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomy ces hygroscopicus. Furthermore, selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where io the selectable marker is on a separate vector.
The vectors of the present invention preferably contain an elements) that permits stable integration of the vector into the host cell genome or autonomous replication of the vec-tor in the cell independent of the genome of the cell.
is The vectors of the present invention may be integrated into the host cell genome when introduced into a host cell.
For integration, the vector may rely on the nucleic acid se-quence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by 2o homologous or non-homologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for di-recting integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a pre-2s cise locations) in the chromosome(s). To increase the likeli-hood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nu-cleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1, 500 base pairs, and most preferably 800 to 1, 500 base pairs, 3o which are highly homologous with the corresponding target se-quence to enhance the probability of homologous recombination.
The integrational elements may be any sequence that is homolo-gous with the target sequence in the genome of the host cell.
Furthermore, the integrational elements may be non-encoding or 3s encoding nucleic acid sequences . On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
s For autonomous replication, the vector may further com-prise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacte-rial origins of replication are the origins of replication of plasmids pBR322, pUCl9, pACYC177, pACYC184, pUB110, pE194, io pTA1060, and pAMi3l. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a muta-tion which makes its functioning temperature-sensitive in the is host cell (see, e.g., Ehrlich, 1978, Proceedings of the Na-tional Academy of Sciences USA 75:1433).
More than one copy of a nucleic acid sequence encoding a polypeptide of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence.
zo Stable amplification of the nucleic acid sequence can be ob-tained by integrating at least one additional copy of the se-quence into the host cell genome using methods well known in the art and selecting for transformants.
The procedures used to ligate the elements described zs above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).
Host Cells 3o The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The term "host cell" encompasses any progeny of a parent cell which is not identical to the parent cell due 3s to mutations that occur during replication.
The cell is preferably transformed with a vector compris-ing a nucleic acid sequence of the invention followed by inte-gration of the vector into the host chromosome. "Transforma-tion" means introducing a vector comprising a nucleic acid se-quence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of io the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.
The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism, e.g., a prokaryote, or i5 a non-unicellular microorganism, e.g., a eukaryote. Useful uni-cellular cells are bacterial cells such as gram positive bacte-ria including, but not limited to, a Bacillus cell, e.g., Ba-cillus alkalophilus, Bacillus amyloliquefaciens, Bacillus bre-vis, Bacillus circulans, Bacillus coagulans, Bacillus lautus, 2o Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces livi-dans or Streptomyces murinus, or gram negative bacteria such as E. coli and Pseudomonas sp. In a preferred embodiment, the bac-z5 terial host cell is a Bacillus lentus, Bacillus licheniformis, Bacillus stearothermophilus or Bacillus subtilis cell. The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using 3o competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electropora tion (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or by conjugation (see, e.g., Koehler and Thorne, 35 1987, Journal of Bacteriology 169:5771-5278).
The host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or a fungal cell.
Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS
s cells, or any number of other immortalized cell lines avail able, e.g., from the American Type Culture Collection.
Examples of suitable mammalian cell lines are the COS (ATCC CRL
1650 and 1651), BHK (ATCC CRL 1632, 10314 and 1573, ATCC CCL
10), CHL (ATCC CCL39) or CHO (ATCC CCL 61) cell lines. Methods io of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159 (1982), 601 - 621; Southern and Berg, J . Mol . Appl . Genet . 1 ( 1982 ) , 32 7 - 341; Loyter et al . , Proc .
Natl. Acad. Sci. USA 79 (1982), 422 - 426; Wigler et al., Cell is 14 (1978), 725; Corsaro and Pearson, Somatic Cell Genetics 7 (1981), 603, Ausubel et al., Current Protocols in Molecular Bi ology, John Wiley and Sons, Inc., N.Y., 1987, Hawley-Nelson et al., Focus 15 (1993), 73; Ciccarone et al., Focus 15 (1993), 80; Graham and van der Eb, Virology 52 (1973), 456; and Neumann 2o et al., EMBO J. 1 (1982), 841 - 845.
In a preferred embodiment, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The zs Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawk-sworth et al., 1995, supra). Representative groups of Ascomy-cota include, e.g., Neurospora, Eupenicillium (=Penicillium), 3o Emericella (=Aspergillus), Eurotium (=Aspergillus), and the true yeasts listed above. Examples of Basidiomycota include mushrooms, rusts, and smuts. Representative groups of Chy-tridiomycota include, e.g., Allomyces, Blastocladiella, Coelo-momyces, and aquatic fungi. Representative groups of Oomycota 3s include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Examples of mitosporic fungi include Aspergil-lus, Penicillium, Candida, and Alternaria. Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
In a preferred embodiment, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporogenous s yeast (Endomycetales), basidiosporogenous yeast, and yeast be longing to the Fungi Imperfecti (Blastomycetes). The ascosporo-genous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four sub-families, Schizosaccharomycoideae (e. g., genus Schizosaccharo-io myces), Nadsonioideae, Lipomycoideae, and Saccharomycoideae (e.g., genera Pichia, Kluyveromyces and Saccharomyces). The basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidi-ella. Yeasts belonging to the Fungi Imperfecti are divided i5 into two families, Sporobolomycetaceae (e. g., genera Sorobolo-myces and Bullera) and Cryptococcaceae (e. g., genus Candida).
Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as de-scribed in Biology and Activities of Yeast (Skinner, F.A., zo Passmore, S.M., and Davenport, R.R., eds, Soc. App. Bacteriol.
Symposium Series No. 9, 1980. The biology of yeast and manipu-lation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B.J., and Stopani, A.O.M., editors, 2nd edition, 1987; The Yeasts, 25 Rose, A.H., and Harrison, J.S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast Saccharomyces, Strathern et al., editors, 1981).
The yeast host cell may be selected from a cell of a spe cies of Candida, Kluyveromyces, Saccharomyces, Schizosaccharo 3o myces, Candida, Pichia, Hansehula, or Yarrowia. In a preferred embodiment, the yeast host cell is a Saccharomyces carlsbergen-sis, Saccharomyces cerevisiae, Saccharomyces diastaticus, Sac-charomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensis or Saccharomyces oviformis cell. Other useful yeast 35 host cells are a Kluyveromyces lactis Kluyveromyces fragilis Hansehula polymorpha, Pichia pastoris Yarrowia lipolytica, Schizosaccharomyces pombe, Ustilgo maylis, Candida maltose, Pichia guillermondii and Pichia methanolio cell (cf. Gleeson et al., J. Gen. Microbiol. 132, 1986, pp. 3459-3465; US 4,882,279 s and US 4,879,231).
In a preferred embodiment, the fungal host cell is a fil-amentous fungal cell. "Filamentous fungi" include all filamen-tous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are io characterized by a vegetative mycelium composed of chitin, cel-lulose, glucan, chitosan, mannan, and other complex polysaccha-rides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding is of a unicellular thallus and carbon catabolism may be fermenta-tive. In a more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, Acre-monium, Aspergillus, Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium, Thielavia, Tolypocladium, and Tricho-2o derma or a teleomorph or synonym thereof . In an even more pre-ferred embodiment, the filamentous fungal host cell is an As-pergillus cell. In another even more preferred embodiment, the filamentous fungal host cell is an Acremonium cell. In another even more preferred embodiment, the filamentous fungal host z5 cell is a Fusarium cell. In another even more preferred embodi-ment, the filamentous fungal host cell is a Humicola cell. In another even more preferred embodiment, the filamentous fungal host cell is a Mucor cell. In another even more preferred em-bodiment, the filamentous fungal host cell is a Myceliophthora 3o cell. In another even more preferred embodiment, the filamen-tous fungal host cell is a Neurospora cell. In another even more preferred embodiment, the filamentous fungal host cell is a Penicillium cell. In another even more preferred embodiment, the filamentous fungal host cell is a Thielavia cell. In an-other even more preferred embodiment, the filamentous fungal host cell is a Tolypocladium cell. In another even more pre-ferred embodiment, the filamentous fungal host cell is a Trichoderma cell. In a most preferred embodiment, the filamen-tous fungal host cell is an Aspergillus awamori, Aspergillus s foetidus, Aspergillus japonicas, Aspergillus niger, Aspergillus nidulans or Aspergillus oryzae cell. In another most preferred embodiment, the filamentous fungal host cell is a Fusarium cell of the section Discolor (also known as the section Fusarium).
For example, the filamentous fungal parent cell may be a Fusa-io rium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sulphureum, or Fusarium trichothecioides cell. In an-ts other preferred embodiment, the filamentous fungal parent cell is a Fusarium strain of the section Elegans, e.g., Fusarium ox-ysporum. In another most preferred embodiment, the filamentous fungal host cell is a Humicola insolens or Humicola lanuginosa cell. In another most preferred embodiment, the filamentous 2o fungal host cell is a Mucor miehei cell. In another most pre-ferred embodiment, the filamentous fungal host cell is a My-celiophthora thermophilum cell. In another most preferred em-bodiment, the filamentous fungal host cell is a Neurospora crassa cell. In another most preferred embodiment, the filamen-ts tous fungal host cell is a Penicillium purpurogenum cell. In another most preferred embodiment, the filamentous fungal host cell is a Thielavia terrestris cell or an Acremonium chry-sogenum cell. In another most preferred embodiment, the Tricho-derma cell is a Trichoderma harzianum, Trichoderma koningii, 3o Trichoderma longibrachiatum, Trichoderma reesei or Trichoderma viride cell. The use of Aspergillus spp. for the expression of proteins is described in, e.g., EP 272 277, EP 230 023.
3s Transformation Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suit-able procedures for transformation of Aspergillus host cells s are described in EP 238 023 and Yelton et al., 1984, Proceed-ings of the National Academy of Sciences USA 81:1470-1474. A
suitable method of transforming Fusarium species is described by Malardier et al., 1989, Gene 78:147-156 or in co-pending US
Serial No. 08/269,449. Examples of other fungal cells are cells io of filamentous fungi, e.g. Aspergillus spp., Neurospora spp., Fusarium spp. or Trichoderma spp., in particular strains of A.
oryzae, A. nidulans or A. niger. The use of Aspergillus spp.
for the expression of proteins is described in, e.g., EP 272277 or EP 230023. The transformation of F. oxysporum may for in-i5 stance be carried out as described by Malardier et al., 1989, Gene 78: 147-156. The transformation of Trichoderma spp. may be performed as known in the art.
Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.I., edi 2o tors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, Journal of Bacteriology 153:163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75:1920. Mammalian cells may be transformed by di-25 rect uptake using the calcium phosphate precipitation method of Graham and Van der Eb (1978, Virology 52:546).
Transformation of insect cells and production of het-erologous polypeptides therein may be performed as described in US 4,745,051; US 4,775,624; US 4,879,236; US 5,155,037; US
30 5,162,222; EP 397,485, all of which are incorporated herein by reference. The insect cell line used as the host may suitably be a Lepidoptera cell line, such as Spodoptera frugiperda cells or Trichoplusia ni cells (cf. US 5,077,214). Culture conditions may suitably be as described in, for instance, WO 89/01029 or 35 WO 89/01028, or any of the aforementioned references.
Transgenic animals It is also within the scope of the present invention to employ transgenic animal technology to produce the present s polypeptide . A transgenic animal is one in whose genome a het erologous DNA sequence has been introduced. In particular, the polypeptide of the invention may be expressed in the mammary glands of a non-human female mammal, in particular one which is known to produce large quantities of milk. Examples of pre-io ferred mammals are livestock animals such as goats, sheep and cattle, although smaller mammals such as mice, rabbits or rats may also be employed.
The DNA sequence encoding the present polypeptide may be introduced into the animal by any one of the methods previously i5 described for the purpose. For instance, to obtain expression in a mammary gland, a transcription promoter from a milk pro-tein gene is used. Milk protein genes include the genes encod-ing casein (cf. US 5,304,489), beta-lactoglobulin, alpha-lactalbumin and whey acidic protein. The currently preferred 2o promoter is the beta-lactoglobulin promoter (cf. Whitelaw et al., Biochem J. 286, 1992, pp. 31-39).
It is generally recognized in the art that DNA sequences lacking introns are poorly expressed in transgenic animals in comparison with those containing introns (cf. Brinster et al., z5 Proc. Natl. Acad. Sci. USA 85, 1988, pp. 836-840; Palmiter et al., Proc. Natl. Acad. Sci. USA 88, 1991, pp. 478-482; Whitelaw et al., Transgenic Res. 1, 1991, pp. 3-13; WO 89/01343; WO
91/02318). For expression in transgenic animals, it is there-fore preferred, whenever possible, to use genomic sequences 3o containing all or some of the native introns of the gene encod-ing the polypeptide of interest. It may also be preferred to include at least some introns from, e.g. the beta-lactoglobulin gene. One such region is a DNA segment which provides for in-tron splicing and RNA polyadenylation from the 3' non-coding 35 region of the ovine beta-lactogloblin gene. when substituted for the native 3' non-coding sequences of a gene, this segment may will enhance and stabilise expression levels of the poly-peptide of interest. It may also be possible to replace the re-gion surrounding the initiation codon of the polypeptide of in-terest with corresponding sequences of a milk protein gene.
s Such replacement provides a putative tissue-specific initiation environment to enhance expression.
For expression of the present polypeptide in transgenic animals, a nucleotide sequence encoding the polypeptide is op-erably linked to additional DNA sequences required for its ex-io pression to produce expression units. Such additional sequences include a promoter as indicated above, as well as sequences providing for termination of transcription and polyadenylation of mRNA. The expression unit further includes a DNA sequence encoding a secretory signal sequence operably linked to the se-i5 quence encoding the polypeptide. The secretory signal sequence may be one native to the polypeptide or may be that of another protein such as a milk protein (cf. von Heijne et al., Nucl.
Acids Res. 14, 1986, pp. 4683-4690; and US 4,873,316).
Construction of the expression unit for use in transgenic 2o animals may conveniently be done by inserting a DNA sequence encoding the present polypeptide into a vector containing the additional DNA sequences, although the expression unit may be constructed by essentially any sequence of legations. It is particularly convenient to provide a vector containing a DNA
as sequence encoding a milk protein and to replace the coding re-gion for the milk protein with a DNA sequence coding for the present polypeptide, thereby creating a fusion which includes expression control sequences of the milk protein gene.
The expression unit is then introduced into fertilized 30 ova or early-stage embryos of the selected host species. Intro duction of heterologous DNA may be carried out in a number of ways, including microinjection (cf. US 4,873,191), retroviral infection (cf. Jaenisch, Science 240, 1988, pp. 1468-1474) or site-directed integration using embryonic stem cells (reviewed 35 by Bradley et al., Bio/Technology 10, 1992, pp. 534-539). The ova are then implanted into the oviducts or uteri of pseudo-pregnant females and allowed to develop to term. Offspring car-rying the introduced DNA in their germ line can pass the DNA on to their progeny, allowing the development of transgenic herds.
General procedures for producing transgenic animals are s known in the art, cf . for instance, Hogan et al . , Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Labo ratory, 1986; Simons et al., Bio/Technology 6, 1988, pp. 179 183; Wall et al., Biol. Reprod. 32, 1985, pp. 645-651; Buhler et al., Bio/Technology 8, 1990, pp. 140-143; Ebert et al., io Bio/Technology 6: 179-183, 1988; Krimpenfort et al., Bio/Technology 9: 844-847, 1991, Wall et al., J. Cell. Biochem.
49: 113-120, 1992; US 4,873,191, US 4,873,316; WO 88/00239, WO
90/05188; WO 92/11757 and GB 87/00458. Techniques for introduc-ing heterologous DNA sequences into mammals and their germ is cells were originally developed in the mouse. See, e.g. Gordon et al., Proc. Natl. Acad. Sci. USA 77: 7380-7384, 1980, Gordon and Ruddle, Science 214: 1244-1246, 1981; Palmiter and Brin-ster, Cell 41: 343-345, 1985; Brinster et al., Proc. Natl.
Acad. Sci. USA 82: 4438-4442, 1985; and Hogan et al. (ibid.).
zo These techniques were subsequently adapted for use with larger animals, including livestock species (see e.g., WO 88/00239, WO
90/01588 and WO 92/11757; and Simons et al., Bio/Technology 6:
179-183, 1988). To summarize, in the most efficient route used to date in the generation of transgenic mice or livestock, sev-2s eral hundred linear molecules of the DNA of interest are in-jected into one of the pro-nuclei of a fertilized egg according to techniques which have become standard in the art . Inj ection of DNA into the cytoplasm of a zygote can also be employed.
3o Transgenic plants Production in transgenic plants may also be employed. It has previously been described to introduce DNA sequences into plants, which sequences code for protein products imparting to the transformed plants certain desirable properties such as in-3s creased resistance against pests, pathogens, herbicides or stress conditions (cf. for instance EP 131 620, EP 205 518, EP
270 355, WO 89/04371 or WO 90/02804), or an improved nutrient value of the plant proteins (cf. for instance EP 90 033, EP 205 518 or WO 89/04371). Furthermore, WO 89/12386 discloses the transformation of plant cells with a gene coding for levansu-s crase or dextransucrase, regeneration of the plant (especially a tomato plant) from the cell resulting in fruit products with altered viscosity characteristics.
In the plant cell, the DNA sequence encoding the present polypeptide is under the control of a regulatory sequence which io directs the expression of the polypeptide from the DNA sequence in plant cells and intact plants. The regulatory sequence may be either endogenous or heterologous to the host plant cell.
The regulatory sequence may comprise a promoter capable of directing the transcription of the DNA sequence encoding the is polypeptide in plants . Examples of promoters which may be used according to the invention are the 35s RNA promoter from cauli-flower mosaic virus (CaMV) , the class I patatin gene B 33 pro-moter, the ST-LS1 gene promoter, promoters conferring seed-specific expression, e.g. the phaseolin promoter, or promoters 2o which are activated on wounding, such as the promoter of the proteinase inhibitor II gene or the wunl or wun2 genes.
The promoter may be operably connected to an enhancer se-quence, the purpose of which is to ensure increased transcrip-tion of the DNA sequence encoding the polypeptide. Examples of as useful enhancer sequences are enhancers from the 5'-upstream region of the 35s RNA of CaMV, the 5'-upstream region of the ST-LS1 gene, the 5'-upstream region of the Cab gene from wheat, the 5'-upstream region of the 1'- and 2'-genes of the TR-DNA of the Ti plasmid pTi ACH5, the 5'-upstream region of the octopine 3o synthase gene, the 5'-upstream region of the leghemoglobin ge-ne, etc.
The regulatory sequence may also comprise a terminator capable of terminating the transcription of the DNA sequence encoding the polypeptide in plants. Examples of suitable termi-35 nators are the terminator of the octopine synthase gene of the T-DNA of the Ti-plasmid pTiACH5 of Agrobacterium tumefaciens, of the gene 7 of the T-DNA of the Ti plasmid pTiACH5, of the nopaline synthase gene, of the 35s RNA-coding gene from CaMV or from various plant genes, e.g. the ST-LS1 gene, the Cab gene s from wheat, class I and class II patatin genes, etc.
The DNA sequence encoding the polypeptide may also be op-erably connected to a DNA sequence encoding a leader peptide capable of directing the transport of the expressed polypeptide to a specific cellular compartment (e.g. vacuoles) or to ex-io tracellular space. Examples of suitable leader peptides are the leader peptide of proteinase inhibitor II from potato, the leader peptide and an additional about 100 amino acid fragments of patatin, or the transit peptide of various nucleus-encoded proteins directed into chloroplasts (e. g. from the St-LS1 gene, i5 SS-Rubisco genes, etc.) or into mitochondria (e.g. from the ADP/ATP translocator).
Furthermore, the DNA sequence encoding the polypeptide may be modified in the 5' non-translated region resulting in enhanced translation of the sequence. Such modifications may, 2o for instance, result in removal of hairpin loops in RNA of the 5' non-translated region. Translation enhancement may be pro-vided by suitably modifying the omega sequence of tobacco mo-saic virus or the leaders of other plant viruses (e. g. BMV, MSV) or of plant genes expressed at high levels (e.g. SS-25 Rubisco, class I patatin or proteinase inhibitor II genes from potato) .
The DNA sequence encoding the polypeptide may furthermore be connected to a second DNA sequence encoding another polypep-tide or a fragment thereof in such a way that expression of 3o said DNA sequences results in the production of a fusion pro-tein. When the host cell is a potato plant cell, the second DNA
sequence may, for instance, encode patatin or a fragment the-reof (such as a fragment of about 100 amino acids).
The plant in which the DNA sequence coding for the poly 3s peptide is introduced may suitably be a dicotyledonous plant, examples of which are a tobacco, potato, tomato, or leguminous (e. g. bean, pea, soy, alfalfa) plant. It is, however, contem-plated that monocotyledonous plants, e.g. cereals, may equally well be transformed with the DNA sequence coding for the en-zyme.
s Procedures for the genetic manipulation of mono-cotyledonous and dicotyledonous plants are well known. In order to construct foreign genes for their subsequent introduction into higher plants, numerous cloning vectors are available which generally contain a replication system for E. coli and a io selectable/screenable marker system permitting the recognition of transformed cells. These vectors include e.g. pBR322, the pUC series, pACYC, M13 mp series etc. The foreign sequence may be cloned into appropriate restriction sites. The recombinant plasmid obtained in this way may subsequently be used for the is transformation of E. coli. Transformed E. coli cells may be grown in an appropriate medium, harvested and lysed. The chi-meric plasmid may then be re-isolated and analyzed. Analysis of the recombinant plasmid may be performed by a . g. determination of the nucleotide sequence, restriction analysis, electrophore-2o sis and other molecular-biochemical methods. After each manipu-lation the sequence may be cleaved and ligated to another DNA
sequence. Each DNA sequence can be cloned on a separate plasmid DNA. Depending on the way used for transferring the foreign DNA
into plant cells other DNA sequences might be of importance. In zs case the Ti-plasmid or the Ri plasmid of Agrobacterium tumefa-ciens or Agrobacterium rhizogenes, at least the right border of the T-DNA may be used, and often both the right and the left borders of the T-DNA of the Ri or Ti plasmid will be present flanking the DNA sequence to be transferred into plant cells.
3o The use of the T-DNA for transferring foreign DNA into plant cells has been described extensively in the prior litera-ture (cf. Gasser and Fraley, 1989, Science 244, 1293 - 1299 and references cited therein). After integration of the foreign DNA
into the plant genome, this sequence is fairly stable at the 3s original locus and is usually not lost in subsequent mitotic or meiotic divisions. As a general rule, a selectable marker gene will be co-transferred in addition to the gene to be trans-ferred, which marker renders the plant cell resistant to cer-tain antibiotics, e.g. kanamycin, hygromycin, 6418 etc. This marker permits the recognition of the transformed cells con-s taming the DNA sequence to be transferred compared to non-transformed cells.
Numerous techniques are available for the introduction of DNA into a plant cell. Examples are the Agrobacterium mediated transfer, the fusion of protoplasts with liposomes containing io the respective DNA, microinjection of foreign DNA, electro-poration etc. In case Agrobacterium mediated gene transfer is employed, the DNA to be transferred has to be present in spe-cial plasmids which are either of the intermediate type or the binary type . Due to the presence of sequences homologous to T-i5 DNA sequences, intermediate vectors may integrate into the Ri-or Ti-plasmid by homologous recombination. The Ri- or Ti-plasmid additionally contains the vir-region which is necessary for the transfer of the foreign gene into plant cells. Interme-diate vectors cannot replicate in Agrobacterium species and are 2o transferred into Agrobacterium by either direct transformation or mobilization by means of helper plasmids (conjugation). (Cf.
Gasser and Fraley, op. cit. and references cited therein).
Binary vectors may replicate in both Agrobacterium spe cies and E. coli. They may contain a selectable marker and a 25 poly-linker region which to the left and right contains the border sequences of the T-DNA of Agrobacterium rhizogenes or Agrobacterium tumefaciens. Such vectors may be transformed di-rectly into Agrobacterium species. The Agrobacterium cell serv-ing as the host cell has to contain a vir-region on another 3o plasmid. Additional T-DNA sequences may also be contained in the Agrobacterium cell.
The Agrobacterium cell containing the DNA sequences to be transferred into plant cells either on a binary vector or in the form of a co-integrate between the intermediate vector and 35 the T-DNA region may then be used for transforming plant cells.
Usually either multicellular explants (e. g. leaf discs, stem segments, roots), single cells (protoplasts) or cell suspen-sions are co-cultivated with Agrobacterium cells containing the DNA sequence to be transferred into plant cells. The plant cells treated with the Agrobacterium cells are then selected s for the co-transferred resistance marker (e.g. kanamycin) and subsequently regenerated to intact plants. These regenerated plants will then be tested for the presence of the DNA se-quences to be transferred.
If the DNA is transferred by e.g. electroporation or mi io croinjection, no special requirements are needed to effect transformation. Simple plasmids e.g. of the pUC series may be used to transform plant cells. Regenerated transgenic plants may be grown normally in a greenhouse or under other condi tions. They should display a new phenotype (e.g. production of i5 new proteins) due to the transfer of the foreign gene(s). The transgenic plants may be crossed with other plants which may either be wild-type or transgenic plants transformed with the same or another DNA sequence. Seeds obtained from transgenic plants should be tested to assure that the new genetic trait is 2o inherited in a stable Mendelian fashion.
See also Hiatt, Nature 344: 469-479, 1990; Edelbaum et al., J. Interferon Res. 12: 449-453, 1992; Sijmons et al., Bio/Technology 8: 217-221, 1990: and EP 255 378.
25 Methods of Production The transformed or transfected host cells described above are cultured in a suitable nutrient medium under conditions permitting the production of the desired molecules, after which these are recovered from the cells, or the culture broth.
3o The medium used to culture the cells may be any conven-tional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements.
Suitable media are available from commercial suppliers or may be prepared according to published recipes (e. g. in catalogues 35 of the American Type Culture Collection). The media are pre-pared using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J.W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, CA, 1991).
If the molecules are secreted into the nutrient medium, s they can be recovered directly from the medium. If they are not secreted, they can recovered from cell lysates. The molecules are recovered from the culture medium by conventional proce dures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous io components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chroma-tographic procedures, e.g. ion exchange chromatography, gelfil-tration chromatography, affinity chromatography, or the like, dependent on the type of molecule in question.
i5 The molecules of interest may be detected using methods known in the art that are specific for the molecules. These de-tection methods may include use of specific antibodies, forma-tion of a product, or disappearance of a substrate. For exam-ple, an enzyme assay may be used to determine the activity of 2o the molecule. Procedures for determining various kinds of ac-tivity are known in the art.
The molecules of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hy-25 drophobic, chromatofocusing, and size exclusion), electropho-retic procedures (e. g., preparative isoelectric focusing (IEF), differential solubility (e. g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
Detailed description of the invention When cell cultures rather than purified substances are used in assays, a complication arises: Cells, cell particles, growth media or matter secreted by the cells can have an effect on the treatment (e. g., heat treatment) of the substance in question, on the assay itself or on the detection of the assay signal.
The present invention provides solutions to these problems.
As it is not feasible to handle individual clones sepa rately, it also becomes necessary with respect to the assay to s level out differences in growth, gene expression and other dif fering characteristics of individual clones, in order to handle many clones simultaneously in an automated manner.
The present invention solves these problems, by defining conditions of growth so as to achieve a uniform distribution of io growth and gene expression in identical clones in the wells of the same microtiter plate (MTP), or by developing a method for doing HTS-assays that are independent of molecule concentra-tions within a broad range. Solutions to these problems include accurate and simple detection of the concentration of the ac-i5 tive molecules, and development of automated assays that incor-porate this information in the protocol during the assay, or that produce raw-data that can be corrected by use of this in-formation after the assay has been performed.
Altogether, the solutions provided by this invention 2o makes microtiter plate based high throughput screening of sub-stances produced by cell cultures a practical and reliable method for the identification of novel substances with inter-esting properties, from large libraries of molecules.
A first preferred embodiment of the invention relates to 25 a method for high throughput screening (HTS) of a large popula tion of host cells for production of a molecule of interest, the method comprising the steps of:
a) arranging the host cells in a spatial array so each posi-tion in the spatial array is occupied by one cell, 3o b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and d) selecting the cells from those positions where the mole-35 cule was produced, as determined in step c).
A method of the first aspect can be performed in many ways, the spatial array of step a) can take on any physical form whatsoever, that enables the assaying of several samples s at once, without one sample contaminating another. Examples of preferred spatial arrays are different kinds of microtiter-plates with any number of wells, such as 96 or 384, and of any kind of material, as well as positions in a High Performance Liquid Chromatography (HPLC) autosampler device. Any kind of io physical arrangement which allows the unambiguous identifica tion of the samples by a number or a position in the array.
Even samples placed as drops on a surface in a specific re corded pattern, the surface being of a solid material or of more complex nature such as a textile or a tissue, e.g. cotton, i5 wool, paper, or cellulose.
A preferred embodiment relates to a method of the first aspect, wherein the spatial array of point a) is a microtiter plate, a solid surface or a textile surface.
A way of carrying out step c) of the first aspect of the 2o invention could be to take a sample from each position of the spatial array, e.g. from a supernatant or cell, and transfer this to another spatial array for further testing or assaying for production of the molecule of interest (see example 2). The second spatial array may be identical to the first one used in z5 the specific method, but may also be of any other kind that fulfils the above mentioned criteria, such as a microtiter plate, a solid surface, a textile, any material etc.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein after step b) a sample is transferred 3o from each position in the spatial array to a position in a sec ond spatial array which is then used onwards in the method, preferably the second array is a microtiter plate, more pref-erably a solid surface, and most preferably a textile surface.
It is a difficult task to make protein libraries in fila 35 mentous fungi. One problem is that the different morphology and growth rate of different clones give rise to large and small clones that tend to grow out of their position in the spatial array. Assaying fungal transformants of different sizes is also a difficult task due to differences in amounts of produced molecules. The present invention solves this by growing the in-s dividual clones/cells within microenvironments in each position of the spatial array (see example 9). Such microenvironments are initially sterile beads or balls of any material that al-lows growth of the clone, preferably beads comprising agarose, alginate, polysaccharide, carbohydrate, alginate, carrageenan, io chitosan, cellulose, pectin, dextran or polyacrylamide, all al-lowing diffusion to/from each micro-environment.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein each position in the spatial array is occupied by a bead comprising one cell, preferably the bead is is an agarose-bead.
The assaying of the first aspect of the invention for production of the molecule of interest can be done in a great number of ways. As indicated, some kinds of spatial arrays like microtiter plates, can sometimes be assayed directly, or sam-zo ples can be taken from each position and transferred to another spatial array for assaying. The assay as such can be based on a number of techniques well known in the art such as antibody binding, ELISA and many others; common to these assays is that a measurement is taken of a detectable property e.g. fluores-2s cence, luminescence, (3-galactosidase or another enzymatic ac-tivity etc. The method of the invention can be performed with any number of these assays, and consequently the molecules as-sayed for in the first aspect step c) can be obtained in a num-ber of ways, depending on the host cell construct. The molecule 30 of interest may be secreted by the host cell into the super-natant, lysis of the host cells may release the molecule or the molecule may remain intracellular.
A preferred embodiment relates to a method of the first aspect, wherein the molecule of interest in the first aspect step c) is 3s assayed in either whole broth, supernatant of cells that se Crete the molecule, a lysate of cells that produce the mole-cule, or is assayed while still inside cells that produce the molecule.
As described above, any number of host cells can be used s to perform the method of the invention.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the host cells are of mammalian ori-gin, preferably hybridoma cells.
More preferably the host cells are of microbial origin, io preferably bacterial or fungal.
Even more preferably the host cells are chosen from the group consisting of Escherichia coli, Bacillus subtilis, Bacil lus licheniformis, Bacillus clausii, Aspergillus niger, Asper gillus oryzae, Aspergillus nidulans, and Saccharomyces cere i5 visiae.
The molecule of interest in the first aspect of the in-vention can be any molecule of biological origin, non-limiting examples of which are peptides, polypeptides, proteins, en-zo zymes, post-translationally modified polypeptides such as lipopeptides or glycosylated peptides, antimicrobial peptides or molecules, primary or secondary metabolites such as algi-nates, small organic molecules, molecules having pharmaceutical properties etc.
z5 Accordingly a preferred embodiment relates to a method of the first aspect, wherein the molecule of interest is chosen from the group consisting of polypeptides, small peptides, lipopeptides, antimicrobials, small molecules and pharmaceuti-cal molecules.
3o Another preferred embodiment relates to a method of the first aspect, wherein the molecule is an enzyme, preferably chosen from the group consisting of amylase, amyloglucosidase, carbohydrase, carboxypeptidase, cellulase, glucoamylase, glu-cose oxidase, glucosidase, haloperoxidase, hemicellulase, in-35 vertase, isomerase, laccase, lipase, lyase, mannosidase, oxi-dase, pectinolytic enzyme, peroxidase, phytase, phenoloxidase, polyphenoloxidase, protease, and transglutaminase.
An obstacle when working with more than one clone is that different clones produce different levels of different vari ants, which means that a quantitative comparison of e.g. mole cule yield between the clones is difficult. The invention pro-vides a way to overcome this obstacle, by growing the clones under conditions that ensure minimal variation in molecule con-centration between the clones. Non-limiting examples of growth io conditions that must be kept essentially equal over the entire spatial array, or similar in each position are temperature, component concentrations in solution (equalize the evaporation from each position, see example 1), amount of molecule produced in each position (see example 9) etc.
is Accordingly a preferred embodiment relates to a method of the first aspect, wherein the growth conditions of the first aspect step b) ensure minimal variation in the molecule concen-tration between all positions in the spatial array.
An obstacle to achieve efficient HTS is how to obtain an 2o accurate determination of the amount of specific active mole cule produced by each individual clone. One solution is to con figure an assay in such a way that it is insensitive to the concentration of the molecule (as exemplified in example 2).
Another solution is that when the concentration of the specific 25 molecule in a position of the spatial array has been deter-mined, this information can be used to determine the specific activity from the total activity determined in that position;
alternatively, the information can be used to adjust the input-amount of the molecule into the activity assay.
3o Non-limiting examples of how the concentration of the specific molecule may be determined are: a) Total molecule measurement. In cases where the molecule of interest is se-creted and makes up a large proportion of the culture super-natant, a total molecule determination will provide a reason-35 able estimate for the amount of specific molecule; b) Specific molecule measurements. The concentration of e.g. a specific molecule such as an enzyme may be determined by any of the fol-lowing methods (see examples):
a.Active site titration of enzymes using a specific enzyme s inhibitor.
b.By using a fluorescently labelled molecule that binds spe cifically to the molecule of interest, and measure the change in fluorescence polarization as the labelled mole cule is added to the culture supernatant containing the io molecule of interest, c. By ELISA measurements using antibodies against the spe-cific protein, including competitive ELISA, d. Co-expression of green fluorescent protein. By transcrip tional (or translational) fusion of a detectable protein i5 (e.g., Green Fluorescent Protein, GFP) and measurement of fluorescense in the enzyme/protein solution, e.Tagging of the enzyme/protein in question, followed by la-belling and subsequent detection (e. g. with fluorescent probe or NMR imaging agent) of the tag.
2o f. Alternatively, the amount of enzyme/protein input into the assay may be controlled (kept constant) by the inclusion of a purification step, e.g. Ni-NTA purification of His-tagged proteins or binding of enzyme/protein to specific antibody.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay of the first aspect step c) is done under conditions where the assay is essentially inde-pendent of the concentration of the molecule.
3o Preferably the molecule is an enzyme, and the enzyme con-centration is in a range of preferably 98% below to 400 % above the average concentration of enzyme employed in the assay, more preferably 50% below to 200% above the average concentration of enzyme employed in the assay.
Another preferred embodiment relates to a method of the first aspect, wherein the assay done in the first aspect step c) is followed by the additional steps of:
a) determining the concentration of the molecule of in-s terest for each position; and b) adjusting the concentration of molecules in each posi-tion to essentially the same level and then performing the assay of the first aspect step c); or c) performing the assay in the first aspect step c) and io then correcting the data obtained with regard to the concentration of the molecule.
Preferably the molecule of interest is an enzyme, and the concentration in step a) of the preceding embodiment is indi-rectly determined by a method chosen from the group consisting is of active site titration using an enzyme inhibitor, measurement of fluorescence polarization using a fluorescently labelled en-zyme inhibitor, measurement of labelled anti-enzyme antibodies, and measurement of a marker protein co-expressed with the en-zyme.
2o An additional preferred embodiment relates to a method of the first aspect, wherein the cultivation of the first aspect step b) is followed by an additional step of recovering from each position essentially the same amount of molecule and using these recovered amounts in the assay of the first aspect step as c) .
Preferably the molecule of the previous embodiment is a polypeptide, and the recovery is achieved by fusing a polyhis-tidine-tag to the polypeptide and recovering this construct on a Ni-NTA solid support.
3o when a screening method is used, the choice of assay de-pends on the molecule of interest and on the host cell con-struct. Many ways are known in the art to assay or monitor the production of a molecule, some in vivo others in vitro. Usually such assays are based on the determination of a chemical or 35 physical event, which may be directly indicative or indirectly through a cascade of events resulting in e.g. a change of col-our in the host cell or in the surrounding medium, emission of light, production of detectable secondary molecules like pro-teins or enzymes, binding of detectable molecules, cell death, cell lysis, cell growth inhibition or promotion (see examples).
s Non-limiting examples of events are:
1. Cleavage or other modification of a substrate in solution.
2. Cleavage or other modification of a substrate (e.g. a stain), covalently or non-covalently attached to textile or other type of solid material, e.g. ceramics, metal surfaces, io plastic or other polymer.
3. Cleavage or other modification of substrate cross-linked/immobilized to bacterial cellulose or other type of polymer surface .
4. Cleavage or other modification of non-stained textile i5 swatches (e. g., cellulose swatch).
5. Interaction with live cells, resulting in lysis, growth in-hibition or growth promotion of these cells.
6. Interaction with another molecule, or group of molecules, leading to a binding event.
ao These events may be detected by e.9. radioactivity, fluo-rescence, fluorescense polarization, luminiscence, NMR, mass spectrometry, absorbance etc. The substance assayed for may be derived from for example cell culture supernatants, lyzed cells or live cells.
25 Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) allows the determination of a chemical or physical event in a live cell, preferably lysis, growth inhibition, growth promotion, production of a protein or another molecule 3o by the cell.
Another preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) allows the determination of an event in which the molecule of interest interacts with another molecule, preferably leading to a binding event or a chemical modification of the other molecule.
Yet another preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect s step c) allows the determination of the cleavage, isomeriza tion, ligation or other modification of a substrate.
Preferably the substrate of the preceding embodiment is a polymer, more preferably chosen from the group consisting of polypeptides, celluloses, polysaccharides, and starches.
io Also, preferably the substrate of the two preceding em-bodiments is immobilized to the surface of a solid material, preferably textile or ceramics.
More preferably the substrate is a solid surface, most preferably a cellulose swatch.
is The substrate of the four preceding embodiments is pref-erably labelled with a detectable probe.
Preferably the probe of the preceding embodiment is fluo-rescent, more preferably it is fluorescein-5-isothiocyanate (FITC) or dichlorotriazino-5-aminofluorescein (DTAF).
2o An industrially very interesting area of research, is the optimization of enzymes to be used in washing applications, consequently the method of the invention is particularly inter-esting in this area of enzyme research. The assay of the first aspect step c) can be carried out under conditions of high pH
is and elevated temperatures by adding detergent, powder or fluid, to the assay and controlling the temperature as well as the shaking.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay of the first aspect step c) 3o is performed in a solution comprising a detergent and where the molecule of interest is an enzyme.
As describe above, a number of assays well known in the art can be used with the present invention, these could be based on any detectable or measurable property that can be as 35 sociated with production of the molecule of interest.
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the assay used in the first aspect step c) involves detection of a signal chosen from the group consisting of fluorescence, fluorescence polarization, absorb-s ance, radioactivity, nuclear magnetic resonance (NMR) and luminiscence.
It was mentioned above how varying concentrations of the molecule in the positions of the spatial array could impair the method of the invention, however not only concentration but io also total amount can vary, and measures can be taken to equal-ize total amount produced of the molecule of interest (see ex-amples 4, 5, 7, and 9).
Accordingly a preferred embodiment relates to a method of the first aspect, wherein the growth conditions of the first i5 aspect step b), have been optimized to give minimal variation in the amount produced of the molecule of interest in each po-sition of the spatial array.
A preferred embodiment relates to a method of the first aspect, wherein the growth conditions are chosen so as to mimic 2o the conditions under full-scale fermentations, preferably high ly dilute media are chosen.
A method for screening a DNA library for DNA of interest according to the second aspect of the invention. An essential element in this method is a step of using the method of the 25 first aspect as described herein.
In the art, ways of generating and producing DNA librar-ies from natural sources are well known, but besides natural DNA sequences, a number of ways are also known in which to gen-erate very large populations of diverse artificial DNA se-3o quences starting from one or more natural sequences, e.g. shuf-fling or directed evolution (WO 98/42832; US 5,965,408; WO
98/01581; WO 97/07205; WO 95/22625; US 5,093,257).
A preferred embodiment relates to a method of the second aspect, wherein the DNA library is generated from a natural DNA
35 sequence by DNA shuffling or directed evolution.
Preferably the host cells of the second aspect step a) are of microbial origin.
A recombinant vector according to the third aspect com prising DNA isolated by a method as defined in the second as s pect of the invention.
A recombinant host cell according to the fourth aspect comprising DNA isolated by a method as described in the second aspect or the vector according to the third aspect.
Preferably the cell according to the fourth aspect is of io microbial origin, even more preferably of Bacillus or Aspergil lus origin, and most preferably chosen from the group consist ing of: Escherichia coli, Bacillus subtilis, Bacillus licheni formis, Bacillus clausii, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, and Saccharomyces cerevisiae.
i5 A transgenic animal according to the fifth aspect con-taining and expressing the DNA of interest according to the second aspect.
A transgenic plant according to the sixth aspect containing and expressing the DNA of interest according to the 2o second aspect.
The industrial interest in the method of the invention is of course spurred by the potential of producing the molecule of interest according to the aspects of the invention. Hence the invention relates to the ways known in the art of producing as such molecules as described in more detail above.
A method of producing a molecule of interest according to the seventh aspect, which method comprises cultivating a cell according to the fourth aspect in suitable culture medium under conditions permitting expression of the DNA of interest and so recovering the resulting molecule from the culture medium.
A method of producing a molecule of interest according to the eight aspect, which method comprises recovering the molecule from any part or secrete of/from the transgenic animal according to the fifth aspect.
35 A method of producing a molecule of interest according to the final aspect, which method comprises growing a cell of a transgenic plant according to the sixth aspect, and recovering the molecule from the resulting plant.
Example 1 s Minimization of evaporation of liquids from microtiter-plates by the use of a culture box.
A culture box was designed in order to minimize evapora-tion of liquids from miniaturized microtiter plate fermenta-tions and analytical methods at temperatures from 30-45°C, or io even 4-99°C. The box is designed with a shallow base to hold wa-ter and absorbent paper. A tray is secured to a base that holds stacks of microtiter plates between stainless steel rods. An airtight lid fitted with a silicon gasket is placed over the base/tray and the lid is secured with clamps on all 4 sides.
i5 Rubber bands are placed around each set of 4 rods that are used to secure the plates into position, such that when the box is placed in an incubator shaker the entire device moves as a sin-gle unit.
Use of the culture box eliminates or minimizes many of 2o the problems associated with miniaturized analytical and fer mentation methods in microtiter plates. By limiting evapora tion, the growth and expression differences across the plate, particularly the differences between clones in the centre and at the edges are minimized. It allows a more uniform growth in as static or shaken cultures, as well as allows adequate oxygena-tion of cultures by rapid plate shaking (up to 400 RPM) for several days. The use of this box allows for a wide variety of experimental conditions to be performed in microtiter plates, e.g. , very low volumes (2 - 20 ml in a 96 well plate) and very 3o dilute solutions (media) may be used without significant loss of volume.
Example 2 Wash performance assay for detergent a.-amylase.
Coating of swatches with starch Unmodified starch from a natural source is mixed with small amounts of fluorescently labelled starch and coated on a solid phase. The natural starch source can be flour derived s from e.g. potato, corn, or rice. Especially rice flour has been observed to provide a good correlation to higher scale wash trials. The solid phase may be twill, as twill has been found to provide good correlation to larger scale washes and has good handling properties. The overall starch concentration as well io as the ratio between labelled and unlabeled starch can be var ied over a wide range, but we have found 50 (w/v) unmodified starch and 0.025% (w/v) fluorescin 5-isothiocyanate (FITC) la belled potato starch (50-300 glucose units per FITC molecule) to provide the best compromise between sensitivity and response i5 level (FITC was obtained from Sigma).
The starches are suspended in water and boiled for 10 min, alternatively jet-cooked for 5 min at 105°C and 2 bar. Af-ter cooling, a selected textile is soaked with the cooked sus-pension, excess slurry removed by rolling, and the textile is 2o dried either overnight at ambient temperature or for a few min-utes at high temperature, e.g. 70°C, at high air velocity, e.g.
12 m/s. We have found that automation of this coating procedure to significantly dampen coating variation. By use of a coating machine to continuously coat several hundred meters at a time, as subsequently performed assays with repeated dose-response curves exhibit considerably less variation compared to non-continuous coatings.
Growth of Bacillus cells secreting a-amylase variants 3o Bacillus cells secreting a-amylase variants are grown in 2xYT and 6 ~g/ml Chloramphenicol for three days at 37°C and 240 rpm, in a culture box (see example 1).
High throughput screen for detergent a,-amylases with better 35 wash performance Dry starch coated textile is punched into wells of a polystyrene microtiter plate, preferentially of the 96-well format. Assays are performed by first applying a detergent so-lution, e.g. 150.1, to each well. A range of detergents can be s used such as liquid detergent or powder detergent dissolved in water. water hardness is controlled by the addition of a de-sired amount of calcium and magnesium ions. The assay itself is insensitive to water hardness over a wide range, e.g. 0-30°dH.
If a detergent that contains enzymes is used, these enzymes can io be inactivated by e.g. heating the detergent to 85°C for 5 min prior to the assay. Furthermore, the detergent can be centri fuged and/or filtered before use to minimise particulate mat ter. However, no assay interference due to un-removed particles has been observed with detergents used in the range of dosages i5 recommended by the manufacturers.
The intrinsic pH of detergents can be enforced with buff-ering capacity by adding e.g. glycine or 3-[cyclohexylamino]-1-propane-sulfonic acid (CAPS). This is an important quality en-hancing measure, since the high throughput screen uses culture 2o supernatants as the source of expressed enzyme. Growth media normally contain buffer components to ensure the optimal growth pH, which is rarely equal to the high pH (often pH 9-11) pre-sent in dissolved detergents.
Culture medium from above is added immediately after dis 25 pensing the detergent. We prefer to use a small amount of en zyme solution compared to detergent/buffer, in order to mini mise artefacts caused by e.g. a rich growth medium. For exam ple, we routinely apply 15 ~1 of enzyme solution to 150 ~,l de tergent.
3o Following addition of detergent and enzyme (culture me-dium), the simulated "wash" takes place. Application of me-chanic motion such as vigorous shaking (e. g., 240 rpm) at this point strongly promotes the effect of tested enzymes, thus cre-ating a good dynamic range for ranking candidates. Incubation 3s times at this step from 5 min to 2 h have been tested. When screening for amylases at low-temperature conditions, we have found 15 min "washing" to provide a good window of difference between "good" or "bad" candidates.
Heating can be applied during incubation to simulate the heating of water during machine washing used in many parts of s the world. For example, simulation of European washing condi tions could include heating up to 40 or 60°C. This heating can be introduced gradually by for example placing the ambient tem-perature microtiter tray in a shaking incubator set to the ap-propriate temperature. By this approach, a heat-up profile is io generated. Alternatively, if constant high temperature is de-sired, heated buffers can be added or insulated tubings and thermostated surroundings can be employed.
The assay responses can be read by transferring the wash solution to another microtiter plate and measure released fluo i5 rescence in this solution. Alternatively, the wash solution can be completely removed and the response measured as residual fluorescence of the swatch.
By using the conditions described above, the two ap proaches generate almost exact mirror image data, meaning that ao a high degree of released fluorescence in a well is reflected by a low degree of residual fluorescence on the corresponding swatch and vice versa. We prefer the last method, as this only requires one well per assay, thus ensuring minimal amounts of operations leading to maximal throughput in e.g. a robotic set z s up .
The growth conditions used ensure a reasonably uniform growth of identical clones in different wells of the plate.
However, large differences in expression level between differ-ent variants still exist. V~Ie have found that amylase variants 3o with different performance in the final application release different amounts of fluorescent stain from the swatch in the wash performance assay, even when the enzyme is used in satu-rating concentrations. Therefore, the screen has been set up using very high concentrations of enzyme. Under these condi-35 tions the stain removal efficiency depends only minimally on the enzyme concentration within a broad range; consequently, differences in expression levels between variants have little effect on the performance of the individual variant in the high throughput screening assay.
when applying the assay to libraries of amylase producing s clones, hits are defined as wells of the plate wherein the measurements exceed a given assay response relative to a se lected benchmark amylase.
Results.
io Correlation with the more application-relevant mini-wash test.
Orange coloured rice starch textile was shaken vigorously in 60 mL Asia-Pacific model detergent containing an amylase va-riant, and the reflectance measured. Table 1 below shows the correlation between the performance of three different amylases i5 ( 1, 2 , and 3 ) in the swatch assay ( the High Throughput Screen ing set-up) and the conventional mini-wash test. The improve ment factor in a given assay is given by the performance of the variant amylase divided by the performance of a given benchmark amylase. Obviously, the improved amylase (amylase 3) performs zo better in both the swatch assay and the mini-wash.
Amylase 1 Amylase 2 Amylase 3 Swatch assay 1.0 0.4 1.1 Mini-wash 1.0 0.3 1.3 Table 1: Relative residual fluorescence intensity on washed swathes compared to relative reflectance of orange coloured as rice starch textile in mini wash. Application dosage of 0.2 ~,g/ml amylase was used for the mini wash, while approx. 2 ~g/ml final dosage was used in the swatch assay (the average concen-tration from culture supernatants in the High Throughput As-say) .
Example 3 HTS screening assay for anti-fungal activity An anti-fungal agent can either inhibit the outgrowth of spores, vegetative cells, or both. To identify an anti-fungal agent inhibiting vegetative cells, 50 ~1 samples of a liquid culture of a tester strain, e.g. Botrytis cinerae, are distrib-s uted into each well of a microtiter plate; 50 ~l of samples of sterile culture supernatants from cultures of bacterial cells, e.g. Bacillus, to be screened for secretion of anti-fungal ac-tivities (e. g. variants of an antimicrobial peptide or enzyme), are then added to each well of the microtiter plate. Option-io ally, instead of sterilizing the culture supernatants, a tissue culture insert (e. g., Nunc TC Insert) may be inserted, to pre-vent contact between the secreting cells and cells of the tester strain. The insert may contain a membrane non-permeable to proteins or other macromolecular components, which allows is the passage of for example small antimicrobial peptides. The microtiter plate is incubated at 30°C for 2-5 days whereafter anti-fungal activity is analysed by optical density measure ments in each well at a suitable wavelength. Low optical den sity indicates the presence of an anti-fungal activity in the 2o well .
Example 4 Use of very dilute media for HTS screening of enzyme-secreting fungi for improved yield.
25 In order to mimic the nutrient limiting conditions of fermentor tanks used for production of for example enzymes, mi-crotiter plate-based screens for improved yield are done in di-lute growth media. The dilution ensures that the nutrients, rather than the oxygen, become the growth limiting factors.
3o This allows a simplification in the handling of the assay since the dilute substrate can be added directly to the cultures, be-cause the effects of the media on the assay will be very weak.
35 Example 5 Use of very dilute media for HTS screening of enzyme-secreting fungi for improved expression General HTS set up for yield mutant screening.
s Mutant libraries of Aspergillus oryzae or Aspergillus niger strains are screened by HTS to identify mutants having increased expression, i.e. improved yield of an enzyme. Better yield mutants expressing for example peroxidase, laccase, lipase, glucose oxidase, amylase, xylanase, phytase, and io aminopeptidase have been identified this way.
For 96-well plate screens, very dilute medium containing 100 - 300 mg/1 carbon-source, ensures carbon-limitation without oxygen limitation.
Primary 96-well plate screens involve the dilution of i5 spores from distinct mutant pools into fermentation substrate so that one spore in average is inoculated per well when 1001 of medium is dispensed into each well. After inoculation, the plates are incubated for 3-4 days at 30-34°C under static con ditions in a culture box (see example 1). The wells are then 2o assayed for enzyme activity, for example by the addition of a substrate solution directly to the growth wells.
Mutants of interest are isolated and single colonies transferred to agar slants. Spores from agar slants are inocu-lated into 96-well plates with approx. 103 spores per well and 25 fermented under static conditions for 4 days at 34°C to retest isolates. Subsequently, selected isolates are tested in shake flask fermentations.
Isolation of mutants having increased Shearzyme~ expression 3o An Aspergillus oryzae transformant MT2181 expressing re-combinant Shearzyme~, was mutated by using UV-irradiation. The MT2181 mutant library was fermented in SH-CDY substrate (pH
6.5) in 96 wells plates as described above. The SH-CDY sub-strate contained pr litre : 0 . 3 g MgS04, 7H20, 0 . 3 g KzS04, 5 . 0 g 35 KHzP04, 0.1 ml tracemetal solution, 0.013 g urea, 0.010 g yeast extract, and 0.1 g maltose. The tracemetal solution contains pr litre: 13.8 g FeS04, 7H20, 8.5 g MnS04, HZO, 14.3 g ZnS04, 7 H20, CuS04, 5 HZO, NiCl2, 6 HZO, 3 g citric acid.
Cultures were then assayed for increased yield, i.e. in-s creased Shearzyme~ activity. Shearzymeo, which is an endoxy-lanase, could be quantitated by using a microtiter plate assay and p-nitrophenyl-(3-D-xylopyranoside (Sigma N-2132) as sub-strate, since the enzyme possesses some exo activity, and yel-low p-nitrophenol was generated. A 100 mg/ml p-nitrophenyl-(3-D-io xylopyranoside stock solution was prepared in DMSO. Subse quently, working substrate was prepared by diluting the stock 10 folds in 0.1 M phosphate buffer (pH 6.0). Standard Shearzyme (BioFeed~ (S), Novo Nordisk A/S, Bagsvaerd, Denmark) was prepared so as to contain 20 FXU/ml in 0.1 M phosphate buffer, pH 6Ø
i5 The standard was stored at -20°C until use. Shearzyme~ stock was diluted appropriately to obtain a standard series ranging from 0.1 to 5.0 FXU/ml just before use. 25 ~,1 samples were dispensed to wells in 96-well plates followed by 120 ~.l of substrate by using a robotic set up. Using a plate reader, the absorbance at zo 405 nm was recorded as the difference of two readings taken at approximately 4 minutes intervals. Shearzyme~ units/ml (FXU/ml) were calculated relative to the Shearzyme~ standards.
In the 96-well primary screen followed by the re-test in z5 96-well plates, 9 mutants from the "MT2181 mutant library" were selected. These mutants produced higher yields of Shearzyme~
than the control strain Aspergillus oryzae MT2181. The 4 Shear-zyme~ producing mutants with highest yields were evaluated in shake flasks. The results obtained are shown in table 2 below 3o where the Shearzyme~ yield of A, oryzae MT2181 as a control is normalized to 100.
96-well re-test Shake flask Strain # (FXU/ml) (FXU/ml) MT2181-6-Ol 126 130 Table 2. Shearzyme expression by Mw~l~l inutanzs As shown in table 2, the 4 selected mutants produce ap proximately 20-30 % more Shearzyme~ than the control strain A.
s oryzae MT2181, when fermented in shake flasks.
Example 6 Screening for cellulase activity using Dichlorotriazino-5-aminofluorescein (DTAF) labelled cotton Swatches.
io Preparation of Cotton swatches Style 400 cotton (Center for Test Materials, PO Box 120, 3130 AC Vlowdingen, Holland) was cut to appropriate sizes. The cotton swatches were swollen in a 0.1 N NaOH solution for 24 is hrs. prior to the labelling in order to enhance the accessibil-ity of the hydroxylic groups to the probe. DTAF dissolved in 0.1 N NaOH was added to the swollen swatches, and the reaction mixture was allowed to react for 24 hrs. at room temperature in the dark on a celloshaker-board. The labelled swatches were 2o washed several times using 0.1 N NaOH, water, MeOH, and finally water again. After the last wash-cycle no probe could be found in the supernatant. The swatches were finally dried. The la belled cotton swatches have a clear yellow colour. Further the DTAF-probe makes the swatches highly fluorescent at the 485/518 2s (excitation/emission) wavelength bands.
Similar fluorescence measurements were obtained whether cotton was labelled in swatches of 5-11 g or whether it had been cut into swatches of approx. 3 mg, suitable for subsequent microtiter plate analysis.
Specific release of fluorescence by incubation of DTAF labelled cotton swatches with purified cellulases Labelled swatches were distributed in each well of a 96 well microtiter plate, washed in deionized water, and incubated with 50 ~,1 cellulase enzyme solution and 150 ~1 buffer for 2h, at 40°C, 400 rpm. The microtiter plates were centrifuged at 2800 rpm and fluorescence intensity (485/518 nm) was measured on 150 ~1 of the supernatant, using a spectrophotometer. The cellu-io lases used were endoglucanase (EG) v, EGV-core, EG I, and CBH
II from Humicola insolens (prepared as described in M.
Schiilein, J. Biotechnology, vol 57, pp. 71-81, 1997).
Table 3 shows that EG V performs much better per endocel lulase activity unit than EG I, EG V-Core or CBH II. This is i5 consistent with the performance of these enzymes in multi-wash experiments to determine their effect. Hence, DTAF-swatches can be used to assay cellulases and the results correlate with the performance of the cellulase in performing a full-scale wash experiments.
2o Further, the signal-to-noise ratio is improved by pre-washing the cotton twenty times in a laundry machine, using ei-ther water or a model detergent, before labelling. Also, the signal-to-noise ratio is improved by increasing the number of labelling cycles.
cellulase EG V
units/ml CBH II EG I EG V core 0,0 24,8 29,0 32,6 29,6 0,9 27,2 33,6 37,7 29,7 2,8 24,5 39,2 37,0 29,7 8,0 21,6 39,4 49,3 32,8 25,0 23,8 50,7 70,2 36,4 75, 0 1 36, 1 57, 6 1 112, 1 61, Table 3. Performance of 4 cellulases in the swatch assay ex-pressed as fluorescence intensity in arbitrary units (example 6) .
s High throughput screening for cellulase activities in cell cul-ture supernatants Recombinant H.insolens cellulase VI (W09901544) was ex-pressed in yeast cells (S.cerevisiae, YNG318) using standard methodologies (Sambrook et al.: "Molecular Cloning. A Laboratory io Manual", Cold Spring Harbor, NY,1989). Transformed cells were grown in SC-ura- media for 3 days at 30°C. 100~.L culture super-natant was transferred to an assay plate containing labelled cellulose swatches as described above. After an appropriate time of incubation the well supernatants were transferred to an is assay plate, and the fluorescence was measured. A control ex periment was performed in 0,2M tris buffer at pH 7 employing 100 ~1 supernatant from yeast cultures expressing either recom binant active cellulase EGVI, or an inactive variant of EGVI.
Clones expressing active cellulases gave rise to higher levels 20 of fluorescence than clones expressing the inactive variant:
EGVI(active): 47.8 +/- 1.1 (n=6) EGVI(inactive): 77.7 +/- 1.9 (n=6) 25 The DTAF labelled cotton swatches can also be used in a cell culture-based screen for active cellulases in a high-throughput format: Yeast cells expressing cellulases are sus-pended in minimal media, and aliquoted into 96 well plates at an average of about 30 wells with growth per 96 well plate (to 30 obtain predominantly single cell isolates). After 3 days of growth at 30°C, 100~L culture supernatant is transferred to an assay plate containing cellulose swatches as described above.
Optionally, a well insert (e.g., Nunc TC Insert) may be in-serted, to separate yeast cells and the cellulose swatch. The 35 insert should contain a membrane permeable to the cellulase en-zyme but not to the cells. After an appropriate time of incuba tion, the well supernatants (without any prior centrifugation) are transferred to an empty assay plate, and the fluorescence is measured for each well. Clones expressing active cellulases s give rise to higher levels of fluorescence.
Example 7 His-tagging/purification of proteases to achieve equal protein input from differentially expressing clones.
io The DNA sequence encoding the protease Savinase~ (Novo Nordisk A/S, Denmark) is translationally fused to a sequence encoding a His6 tag and libraries of Savinase~-His6 variants are produced and introduced into Bacillus. After standard growth, a limited number of Savinase~ enzymes of each variant (about 100 i5 of what is secreted by Bacillus carrying the wildtype Savinase gene) are immobilized in the wells of Ni-NTA microtiter plates.
The unbound fraction including cells and excess Savinase~ is re-moved, the plate washed once or twice in a buffer containing 5-20 mM Imidazole. The His-tagged Savinase~ variants are released zo from the solid support by the addition of 250 mM Imidazole, and aliquots of the supernatants from each well are used as input in a wash performance assay as described in the previous exam-ples.
z5 Example 8 Determination of Savinase~ concentration by fluorescence polari-zation measurements.
The CI-2 protease inhibitor is labelled by standard means with a fluorescent probe. After growth as described above, the 3o amount of a Savinase~ variant in a given well may be measured directly in the wells by addition of fluorescence-labelled in-hibitor which upon binding to the protease changes rotational speed. The rotational speed may be monitored by fluorescence polarization analysis or by other means which monitors diffu-35 sion (e.g. fluorescence correlation spectroscopy). Since the amount of Savinase~ variant may vary significantly between the individual wells, the fluorescently labelled CI-2 inhibitor is added in two or three steps of defined amounts and the fluores-cence polarisation is measured after each CI-2 addition. The determined concentration of Savinase~ variant in the individual s well may be used to adjust the input volume from this well into the activity assay, or can be used to correct the obtained ac-tivity data, in order to determine the specific activity of the Savinase~ variant of that well.
io Example 9 High throughput screening in filamentous fungi It is a difficult task to make protein libraries in fila-mentous fungi. One problem is the different morphology and growth rate of different clones. This gives rise to large and i5 small clones, as well as clones that might be outcompeted by other clones. Assaying fungal transformants of different sizes is also a difficult task due to differences in amounts of ex-pressed enzymes. Another problem is the handling of all the clones on the plate.
2o These problems can be overcome by growing the individual clones in alginate balls with a high molecular weight (HMW) dextran as carbon source, and then using the~balls as the sour ce of clonal cell cultures in a microtiter plate . The HMW dex tran lets the slow-growing transformants outgrow, without cross z5 contamination from faster growing transformants.
A Polymerase chain reaction, using pAHL (carrying a Li-pase gene) as the template and 2 pmol/ml of each primer: oligo 115120: (GCTTTGTGCAGGGTAAATC), and oligo 134532: (GAGCAATAT-CAGGCCGCGCACG) is run under the following conditions: 94°C, 5 3o min.; 30 cycles of (94°C, 30 sec.; 50°C, 30 sec.;
72°C, 1 min.), and 72°C, 5 min. and a commercial Taq polymerase, such as Am-pliTaq, (Perkin-Elmer Corp., Branchburg NJ, USA). For example, the PCR conditions 'may result in a high rate of error, and therefore a library of Lipase mutants are generated.
35 Protoplasts of the filamentous fungi strain JaL250 is transformed using 2~.g of pENI1298, which had been digested with Ball and SgrAl to remove most of the lipase encoding sequence, and 5~,g of the above PCR product . The vector and the PCR frag-ment are allowed to recombine in vivo as described in WO
97/07205.
s The protoplasts are washed twice with ST (0.6M sorbitol, 100mM TRIS pH7.0) in order to remove CaCl2. The protoplasts are then re-suspended in an alginate solution (1.5% alginate, 2 0 high molecular weight dextran (5-40*106 kd), 1.2 M sorbitol, 10 mM TRIS pH7.5) . Using a pump, the suspension is pumped through io a small nozzle where small suspension droplets are made. These drops fall down (15 cm) into a shake flask (500m1) containing 0.2M CaCl2, 1.2 M sorbitol, 10 mM TRIS pH7.5. Droplets of an al-ginate solution (typically 1-2 %) turn into hard balls when they encounter a CaClz solution (such as a 0.2 M solution).
i5 Small alginate balls of the size 2.5 mm in diameter are gener-ated by this procedure. The protoplast suspension should be made so that approximately 1 out of 5 balls contains a trans-formed protoplast, in order to avoid multiple clones in the same ball.
zo The protoplast-containing alginate balls are grown over-night at 30°C degrees in STC (10 mM CaCl2, 1.2 M sorbitol, 10 mM
TRIS pH7.5) in order to regenerate the cell wall. After a cou-ple of washes in sterile water to remove sorbitol, the balls are transferred to 1* Vogel media and grown 2-3 days at 30°C de-25 grees. The sole carbon source is the dextran in the balls. This prevents cross-contamination from ball to ball, and allows slow-growing transformants to gain reasonable biomass.
The alginate balls are transferred to a microtiter plate;
one ball into each microtiter well. Liquid growth media is 3o added to the wells and after a period of growth incubation, the growth media is analyzed for lipase activity under the desired conditions.
Claims (42)
1. A method for high throughput screening (HTS) of a large population of host cells for production of a molecule of inter-est, the method comprising the steps of:
a) arranging the host cells in a spatial array so each posi-tion in the spatial array is occupied by one cell, b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and d) selecting the cells from those positions where the mole-cule was produced, as determined in step c).
a) arranging the host cells in a spatial array so each posi-tion in the spatial array is occupied by one cell, b) cultivating the host cells under growth conditions suit-able for HTS, c) assaying each array position for production of the mole-cule of interest, and d) selecting the cells from those positions where the mole-cule was produced, as determined in step c).
2. The method according to claim 1, wherein the spatial array of point a) is a microtiter plate, a solid surface or a textile surface.
3. The method according to claim 1 or 2, wherein after step b) a sample is transferred from each position in the spatial array to a position in a second spatial array which is then used on-wards in the method, preferably the second array is a micro-titer plate, more preferably a solid surface, and most prefera-bly a textile surface.
4. The method according to any of claims 1 - 3, where each po-sition in the spatial array is occupied by a bead comprising one cell, preferably the bead is an agarose-bead.
5. The method according to any of claims 1 - 4, wherein the molecule of interest in claim 1 step c) is assayed in either whole broth, supernatant of cells that secrete the molecule, a lysate of cells that produce the molecule, or is assayed while still inside cells that produce the molecule.
6. The method according to any of claims 1 - 5, wherein the host cells are of mammalian origin, preferably hybridoma cells.
7. The method according to any of claims 1 - 5, wherein the host cells are of microbial origin, preferably bacterial or fungal.
8. The method according to claim 7, wherein the host cells are chosen from the group consisting of Escherichia coli, Bacillus subtilis, Bacillus licheniformis, Bacillus clausii, Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, and Saccharo-myces cerevisiae.
9. The method according to any of claims 1 to 8, wherein the molecule of interest is chosen from the group consisting of polypeptides, small peptides, lipopeptides, antimicrobials, small molecules and pharmaceutical molecules.
10. The method according to any of claims 1 to 8, wherein the molecule is an enzyme, preferably chosen from the group con-sisting of amylase, amyloglucosidase, carbohydrase, carboxypep-tidase, cellulase, glucoamylase, glucose oxidase, glucosidase, haloperoxidase, hemicellulase, invertase, isomerase, laccase, lipase, lyase, mannosidase, oxidase, pectinolytic enzyme, per-oxidase, phytase, phenoloxidase, polyphenoloxidase, protease, and transglutaminase.
11. The method according to any of claims 1 to 10, wherein the growth conditions of claim 1 step b) ensure minimal variation in the molecule concentration between all positions in the spa-tial array.
12. The method according to any of claims 1 to 11, wherein the assay of claim 1 step c) is done under conditions where the as-say is essentially independent of the concentration of the mo-lecule.
13. The method according to claim 12, where the molecule is an enzyme, and where the enzyme concentration is in a range of preferably 98% below to 400% above the average concentration of enzyme employed in the assay, more preferably 50% below to 200 % above the average concentration of enzyme employed in the as-say.
14. The method according to any of claims 1 to 13, wherein the assay done in claim 1 step c) is followed by the additional steps of:
a) determining the concentration of the molecule of in-terest for each position; and b) adjusting the concentration of molecules in each posi-tion to essentially the same level and then performing the assay of claim 1 step c); or c) performing the assay in claim 1 step c) and then cor-recting the data obtained with regard to the concentra-tion of the molecule.
a) determining the concentration of the molecule of in-terest for each position; and b) adjusting the concentration of molecules in each posi-tion to essentially the same level and then performing the assay of claim 1 step c); or c) performing the assay in claim 1 step c) and then cor-recting the data obtained with regard to the concentra-tion of the molecule.
15. The method according to claim 14, wherein the molecule of interest is an enzyme, and wherein the concentration in claim 14 step a) is indirectly determined by a method chosen from the group consisting of active site titration using an enzyme in-hibitor, measurement of fluorescence polarization using a fluo-rescently labelled enzyme inhibitor, measurement of labelled anti-enzyme antibodies, and measurement of a marker protein co-expressed with the enzyme.
16. The method according to any of claims 1 - 15, wherein the cultivation of claim 1 step b) is followed by an additional step of recovering from each position essentially the same amount of molecule and using these recovered amounts in the as-say of claim 1 step c).
17. The method according to claim 16, wherein the molecule is a polypeptide, and where the recovery is achieved by fusing a polyhistidine-tag to the polypeptide and recovering this con-struct on a Ni-NTA solid support.
18. The method according to any of claims 1 - 17, where the as-say used in claim 1 step c) allows the determination of a chemical or physical event in a live cell, preferably lysis, growth inhibition, growth promotion, production of a protein or another molecule by the cell.
19. The method according to any of claims 1 - 17, where the as-say used in claim 1 step c) allows the determination of an event in which the molecule of interest interacts with another molecule, preferably leading to a binding event or a chemical modification of the other molecule.
20. The method according to any of claims 1 - 17, where the as-say used in claim 1 step c) allows the determination of the cleavage, isomerization, ligation or other modification of a substrate.
21. The method according to claim 20, where the substrate is a polymer, preferably chosen from the group consisting of poly-peptides, celluloses, polysaccharides, and starches.
22. The method according to claim 20 or 21, where the substrate is immobilized to the surface of a solid material, preferably textile or ceramics.
23. The method according to any of claims 20 - 22, where the substrate is a solid surface, preferably a cellulose swatch.
24. The method according to any of claims 20 to 23, where the substrate is labelled with a detectable probe.
25. The method according to claim 24, where the probe is fluo-rescent, preferably fluorescein-5-isothiocyanate (FITC) or di-chlorotriazino-5-aminofluorescein (DTAF).
26. The method according to any of claims 1-25, where the as-say of claim 1 step c) is performed in a solution comprising a detergent and where the molecule of interest is an enzyme.
27. The method according to any of claims 1-26, where the assay used in claim 1 step c) involves detection of a signal chosen from the group consisting of fluorescence, fluorescence polarization, absorbance, radioactivity, nuclear magnetic reso-nance (NMR) and luminescence.
28. The method according to any of claims 1-27, where the growth conditions of claim 1 step b), have been optimized to give minimal variation in the amount produced of the molecule of interest in each position of the spatial array.
29. The method according to any of claims 1-28, where the growth conditions are chosen so as to mimic the conditions un-der full scale fermentations, preferably highly dilute media are chosen.
30. A method for screening a DNA library for DNA of interest, the method comprising the steps of:
a) creating host cells comprising the DNA library, b) using the method described in claim 1 to assay for a host cell producing a molecule of interest; wherein the host cell comprises the DNA of interest.
a) creating host cells comprising the DNA library, b) using the method described in claim 1 to assay for a host cell producing a molecule of interest; wherein the host cell comprises the DNA of interest.
31. The method according to claim 30, wherein the DNA library is generated from a natural DNA sequence by DNA shuffling or directed evolution.
32. The method according to claim 30, wherein the host cells of step a) are of microbial origin.
33. A recombinant vector comprising DNA isolated by a method as defined in any of claims 30-32.
34. A recombinant host cell comprising DNA isolated by a method as described in any of claims 30-32 or the vector according to claim 33.
35. The cell according to claim 34, which is of microbial ori-gin.
36. The cell according to claim 35, which is of Bacillus or As-pergillus origin.
37. The cell according to claim 36, which is chosen from the group consisting of: Escherichia coli, Bacillus subtilis, Ba-cillus licheniformis, Bacillus clausii, Aspergillus niger, As-pergillus oryzae, Aspergillus nidulans, and Saccharomyces cere-visiae.
38. A transgenic animal containing and expressing the DNA of interest according to any of claims 30-32.
39. A transgenic plant containing and expressing the DNA of interest according to any of claims 30-32.
40. A method of producing a molecule of interest, which method comprises cultivating a cell according to any of claims 34-37 in suitable culture medium under conditions permitting expression of the DNA of interest and recovering the resulting molecule from the culture medium.
41. A method of producing a material of interest, which method comprises recovering the molecule from any part or secrete of/from the transgenic animal according to claim 38.
42. A method of producing a molecule of interest, which method comprises growing a cell of a transgenic plant according to claim 39, and recovering the molecule from the resulting plant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199901605 | 1999-11-05 | ||
DKPA199901605 | 1999-11-05 | ||
PCT/DK2000/000568 WO2001032844A1 (en) | 1999-11-05 | 2000-10-10 | Microtiter plate (mtp) based high throughput screening (hts) assays |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2388982A1 true CA2388982A1 (en) | 2001-05-10 |
Family
ID=8106475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002388982A Abandoned CA2388982A1 (en) | 1999-11-05 | 2000-10-10 | Microtiter plate (mtp) based high throughput screening (hts) assays |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1230348A1 (en) |
AU (1) | AU7646200A (en) |
CA (1) | CA2388982A1 (en) |
WO (1) | WO2001032844A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
AU2002361220A1 (en) * | 2001-12-31 | 2003-07-15 | Institut Fur Physikalische Hochtechnologie E.V. | Micro-recess array for size-dependent sorting or separation of cells suspended in a flowing medium and method for analysing the functional activity of individual cells |
WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
WO2004090549A1 (en) * | 2003-04-11 | 2004-10-21 | Novozymes A/S | Method of screening for secreted glycosylated polypeptides |
EP1477805A1 (en) | 2003-05-12 | 2004-11-17 | ProBioGen AG | Method for cell selection |
EP1658378A2 (en) * | 2003-08-19 | 2006-05-24 | Novozymes A/S | Active-site titration of glycosyl hydrolases |
AU2005269527B2 (en) | 2004-07-26 | 2011-12-01 | Pfenex Inc. | Process for improved protein expression by strain engineering |
US7655421B2 (en) * | 2005-06-17 | 2010-02-02 | Ciencia, Inc. | Cytometer on a chip |
US9580719B2 (en) * | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CA2685326A1 (en) * | 2007-04-27 | 2008-11-06 | Dow Global Technologies Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654150A (en) * | 1995-06-07 | 1997-08-05 | President And Fellows Of Harvard College | Method of expression cloning |
EP0950184A1 (en) * | 1996-06-27 | 1999-10-20 | Cellstat Technologies, Inc. | High-throughput screening method and apparatus |
AU3753599A (en) * | 1998-04-24 | 1999-11-16 | Genova Pharmaceuticals Corporation | Micro-compartmentalization device and uses thereof |
AU4194899A (en) * | 1998-05-21 | 1999-12-06 | Hyseq, Inc. | Linear arrays of immobilized compounds and methods of using same |
-
2000
- 2000-10-10 EP EP00965865A patent/EP1230348A1/en not_active Withdrawn
- 2000-10-10 AU AU76462/00A patent/AU7646200A/en not_active Abandoned
- 2000-10-10 CA CA002388982A patent/CA2388982A1/en not_active Abandoned
- 2000-10-10 WO PCT/DK2000/000568 patent/WO2001032844A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1230348A1 (en) | 2002-08-14 |
WO2001032844A1 (en) | 2001-05-10 |
AU7646200A (en) | 2001-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8569029B2 (en) | DNase expression in recombinant host cells | |
US7794962B2 (en) | High-throughput screening of expressed DNA libraries in filamentous fungi | |
EP1276857B1 (en) | Signal sequence trapping | |
US9045748B2 (en) | Methods for transforming and expression screening of filamentous fungal cells with a DNA library | |
WO1999061651A2 (en) | Methods for producing a polypeptide by modifying the copy number of a gene | |
CA2388982A1 (en) | Microtiter plate (mtp) based high throughput screening (hts) assays | |
JP2005514911A6 (en) | DNA sequence for transcriptional regulation | |
JP2005514911A (en) | DNA sequence for transcriptional regulation | |
US20080058214A1 (en) | Signal sequence trapping | |
JP3910634B2 (en) | Transformant producing PF1022 substance and method for transforming bacteria belonging to filamentous fungi | |
WO2001032829A2 (en) | Methods to screen microorganisms or gene libraries for products secreted from a cell | |
CN107667177A (en) | Method for selecting the enzyme with enhancing activity | |
CA2425380A1 (en) | Transgenic plants | |
EP2078078B1 (en) | Selection of well-expressed synthetic genes | |
WO2001032858A1 (en) | A high throughput screening (hts) method | |
KR100825290B1 (en) | System of Biomolecular Fluorescence Complementation Containing a Cell Inserted a Part of Fluorescence Protein Gene In Chromosome and Methods of Biomolecular Fluorescence Complementation By Using It | |
CN111778270B (en) | Method for reflecting in vitro cell-free protein expression level by integrating luminescent reporter gene | |
WO2001032834A1 (en) | A method of screening cell populations | |
AU779195B2 (en) | High throughput screening (HTS) assays for protein variants with reduced antibody binding capacity | |
WO2001049878A1 (en) | FUNGAL EXTRACELLULAR Fam35 BETA-GALACTOSIDASES | |
CN118406577A (en) | Recombinant pichia pastoris for displaying SHP2, construction method and application thereof | |
WO2005024012A1 (en) | Increased expression of a modified polypeptide | |
US20110045482A1 (en) | Screening methods for identifying target antifungal genes and compounds by detecting cell surface glycoproteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |